selected scholarly activity
-
chapters
- Direct Oral Anticoagulant Reversal for Management of Bleeding and Emergent Surgery. 71-91. 2021
- Acute Coronary Syndromes. 2142-2151.e2. 2018
- Acute Coronary Syndromes. 2142-2151.e2. 2017
- Anticoagulation in acute coronary syndromes. 171-196. 2016
- Venous Thrombosis. 619-626. 2013
- New and upcoming oral anticoagulants. 218-220. 2012
- Antithrombotic Therapy after Heart Valve Replacement. 957-967. 2009
- Major Vascular Complications in Patients Undergoing Non‐Cardiac Surgery: Magnitude of the Problem, Risk Prediction, Surveillance, and Prevention. 47-62. 2009
- Cyclooxygenase Inhibitors. 31-46. 2008
- Thrombolytic Therapy for Deep Vein Thrombosis and Pulmonary Embolism. 88-98. 2008
- Emerging oral antiplatelet receptor inhibitors. 119-126. 2008
- Emerging anticoagulants and heparin-induced thrombocytopenia: Indirect and direct factor XA inhibitors and oral thrombin inhibitors. 441-461. 2007
-
conferences
- Individual lifetime benefit from low-dose colchicine in patients with chronic coronary artery disease. European Journal of Preventive Cardiology (EJPC). 1950-1962. 2023
- Lipoprotein(a) and Oxidized Phospholipids on Lipoproteins and Cardiovascular Outcomes in Patients With Chronic Coronary Syndrome Treated With Colchicine. Circulation. 2023
- Residual Stroke Risk Among Atrial Fibrillation Patients Treated With Warfarin or Novel Oral Anticoagulants: A Patient Level MetaAnalysis From Combine AF. Circulation. 2023
- Efficacy and Safety of NOACs vs. Warfarin Across the Continuous Range of Body Mass Index and Body Weight: Insights From COMBINE-AF. Circulation. 2022
- End-of-trial inflammatory biomarkers, lipid levels, creatine kinase and markers of renal and liver function in the LoDoCo2 trial. European Heart Journal. 1266-1266. 2022
- The effects of colchicine in patients with diabetes mellitus and chronic coronary artery disease: a post-hoc analysis of the LoDoCo2-trial. European Heart Journal. 2401-2401. 2022
- ABC-AF STROKE AND BLEEDING SCORES ARE USEFUL TOOLS TO ESTIMATE THE BALANCE BETWEEN BENEFITS AND RISKS WITH DIFFERENT ANTITHROMBOTIC TREATMENTS IN PATIENTS WITH ATRIAL FIBRILLATION: INSIGHTS FROM THE ARISTOTLE AND RE-LY TRIALS. Journal of the American College of Cardiology. 162-162. 2022
- Effects Of Oral Factor Xa Inhibitors On Ischemic Stroke In Patients Without Atrial Fibrillation: Systematic Review Of Randomized Clinical Trials. Stroke. 2022
- Bone Morphogenetic Protein 10-A Novel Biomarker of Ischemic Stroke in Patients With Atrial Fibrillation. Circulation. 2021
- Estimating Cardiovascular and Limb Benefits of Combined Contemporary Risk Reduction Therapies in Patients with Symptomatic Peripheral Artery Disease: An Analysis of Randomized Controlled Trials. Circulation. 2021
- NT-proBNP is Associated with Stroke, Heart Failure Hospitalizations, and Death in Patients with Atrial Fibrillation Without Oral Anticoagulation Regardless of Heart Rhythm. Circulation. 2021
- Combination Antithrombotic Treatment for prevention of recurrent Ischemic Stroke in IntraCranial Atherosclerotic Disease: CATIS-ICAD. Neurology. 2020
- Rivaroxaban Plus Aspirin versus With Aspirin in Patients With Prior Percutaneous Coronary Intervention (PCI): Insights From the COMPASS Trial. Circulation. E985-E986. 2019
- Absence of Coronary Artery Disease by Coronary Angiography is Associated With a Lower Risk of Myocardial Infarction Than in the General Population. Circulation. 2019
- Rivaroxaban Plus Aspirin versus With Aspirin in Patients With Prior Percutaneous Coronary Intervention (PCI): Insights From the COMPASS Trial. Circulation. 2019
- Apixaban Versus Dalteparin for Thromboprophylaxis in Patients with Acute Spinal Cord Injury: A Pilot Study. Blood. 2434-2434. 2019
- Effects of Andexanet Alfa on Thrombin Generation in Bleeding Associated with Factor Xa Inhibitors. Blood. 711-711. 2019
- Diabetes mellitus is a risk factor for ischemic stroke in patients with and without coronary artery disease after coronary angiography. European Heart Journal. 93-93. 2019
- Estimating individual lifetime benefit and bleeding risk of adding rivaroxaban to aspirin for patients with stable cardiovascular disease: results from the COMPASS trial. European Heart Journal. 1274-1274. 2019
- Risk factors and clinical outcomes in chronic CAD and PAD: an analysis of the randomized, double-blind COMPASS trial. European Heart Journal. 2472-2472. 2019
- The applicability of the dual pathway approach criteria after coronary angiography. European Heart Journal. 832-832. 2019
- Thrombotic events in bleeding patients treated with andexanet alpha: an ANNEXA-4 sub-study. European Heart Journal. 94-94. 2019
- A RANDOMIZED TRIAL OF PROTON PUMP INHIBITORS VERSUS PLACEBO TO PREVENT UPPER GASTROINTESTINAL BLEEDING IN PATIENTS RECEIVING RIVAROXABAN OR ASPIRIN. Gastroenterology. S174-S174. 2019
- ADVERSE EVENTS RELATED TO PROTON PUMP INHIBITOR THERAPY. RESULTS OF A RANDOMIZED TRIAL OF PANTOPRAZOLE VERSUS PLACEBO WITH 53,152 PATIENT YEARS OF FOLLOW-UP. Gastroenterology. S173-S174. 2019
- Andexanet alfa for treatment of factor Xa inhibitor-related acute major bleeding. Journal of Thrombosis and Thrombolysis. 608-608. 2019
- EFFECTS OF PROTON-PUMP INHIBITORS IN PATIENTS RECEIVING CLOPIDOGREL-BASED ANTITHROMBOTIC THERAPY FOR CARDIOVASCULAR PREVENTION: A SYSTEMATIC REVIEW AND META-ANALYSIS OF RANDOMIZED TRIALS. Gastroenterology. S97-S97. 2019
- CARDIOVASCULAR EVENTS IN PATIENTS RECEIVING SULODEXIDE VERSUS CONTROL: SYSTEMATIC REVIEW AND META-ANALYSIS OF RANDOMIZED CONTROLLED TRIALS. Journal of the American College of Cardiology. 144-144. 2019
- LONG-TERM TREATMENT WITH APIXABAN OF PARTICIPANTS FOLLOWING CONCLUSION OF AVERROES. Journal of the American College of Cardiology. 324-324. 2019
- Effect of Oral Factor Xa Inhibitors on the Risk of Subdural Hematoma: COMPASS trial Results and Systematic Review. Stroke. 2019
- ANDEXANET ALFA REVERSES ANTICOAGULATION IN FACTOR XA-ASSOCIATED MAJOR BLEEDING IN ANNEXA-4 STUDY. Critical Care Medicine. 2019
- Rivaroxaban Thromboprophylaxis in High-Risk Ambulatory Cancer Patients Receiving Systemic Therapy: Results of a Randomized Clinical Trial (CASSINI). Blood. 2018
- GDF-15 is Associated With Major Bleeding and Death Independent of Geographic Regions in Patients With Atrial Fibrillation. Circulation. 2018
- A novel model for prediction of ischemic stroke in patients without atrial fibrillation. European Heart Journal. 1273-1273. 2018
- Applicability of the COMPASS trial in a Danish all-comers coronary angiography cohort: an analysis of the Western Denmark heart registry. European Heart Journal. 851-851. 2018
- RENAL IMPAIRMENT DOES NOT COMPROMISE DABIGATRAN REVERSAL BY IDARUCIZUMAB. Journal of the American College of Cardiology. A2045-A2045. 2018
- A Randomized Controlled Trial of Continued versus Interrupted Novel Oral Anti-Coagulant at the Time of Device Surgery (BRUISE CONTROL-2). Circulation. E450-E450. 2017
- Costs Impact Rivaroxaban Plus Aspirin versus Aspirin in the COMPASS Trial. Circulation. E456-E457. 2017
- Impact of Rivaroxaban Alone or in Combination With Aspirin versus Aspirin in Preventing Graft Occlusion in Patients With CABG Surgery COMPASS CABG. Circulation. 2017
- Analysis of Red Blood Cell Storage Duration and in-Hospital Mortality Using Time Dependent Exposure: Is the Oldest Blood Bad?. Transfusion. 33A-33A. 2017
- A meta-analysis of INR targets for mechanical heart valves: we need new evidence. European Heart Journal. 417-417. 2017
- A novel biomarker-based risk score to predict death in patients with atrial fibrillation: Insights from the ARISTOTLE and RE-LY trials. European Heart Journal. 1221-1221. 2017
- Andexanet Alfa for the Management of Acute Major Bleeding Associated with FXa Inhibitors (P5.059). Neurology. 2017
- THE PRESCRIBING OF ANTIPLATELET THERAPY ONLY IN PATIENTS WITH NONVALVULAR ATRIAL FIBRILLATION: RESULTS FROM THE GARFIELD-AF REGISTRY. Journal of the American College of Cardiology. 326-326. 2017
- Idarucizumab For Dabigatran Reversal: Updated Results Of The Re-verse Ad Study. Circulation. E714-E715. 2016
- Bleeding in Patients with Atrial Fibrillation Treated with Different Doses of Direct Oral Anticoagulants and Vitamin K Antagonists: A Population-Based Study. Blood. 2617-2617. 2016
- Comparison of Contemporary Bleeding Risk Scores in Patients With Non-Valvular Atrial Fibrillation Treated With Dabigatran or Warfarin: Insights From the RE-LY Trial. Circulation. 2016
- Informing Fresh Versus Old Red Cell Management (INFORM) Trial: A Large International Pragmatic Randomized Trial. Transfusion. 5A-5A. 2016
- Cardiac biomarkers and left ventricular hypertrophy in relation to outcomes in patients with atrial fibrillation: experiences from the RELY trial. Journal of the American Heart Association. 47-47. 2016
- Growth differentiation factor 15 is an independent marker of risk of major bleeding in atrial fibrillation: insights from the RE-LY trial. European Heart Journal. 429-429. 2016
- Anticoagulants: Myths, mysteries and realities. Vasomed. 111-112. 2016
- Comparison of locally measured activated partial thromboplastin time (aPTT) to central laboratory aPTT when measuring reversal of dabigatran using idarucizumab. Journal of Thrombosis and Haemostasis. 30-30. 2016
- CHA2DS2-VASC VERSUS HAS-BLED SCORE FOR PREDICTING RISK OF MAJOR BLEEDING AND ISCHEMIC STROKE IN ATRIAL FIBRILLATION: INSIGHTS FROM RE-LY TRIAL. Journal of the American College of Cardiology. 1889-1889. 2016
- EXTERNAL VALIDATION OF THE BIOMARKER-BASED ABC-BLEEDING RISK SCORE FOR ATRIAL FIBRILLATION. Journal of the American College of Cardiology. 893-893. 2016
- EXTERNAL VALIDATION OF THE BIOMARKER-BASED ABC-STROKE RISK SCORE FOR ATRIAL FIBRILLATION. Journal of the American College of Cardiology. 879-879. 2016
- IDARUCIZUMAB FOR REVERSAL OF THE ANTICOAGULANT EFFECTS OF DABIGATRAN IN PATIENTS IN AN EMERGENCY SETTING OF MAJOR BLEEDING, URGENT SURGERY, OR INTERVENTIONS. Journal of the American College of Cardiology. 664-664. 2016
- Idarucizumab reversal of anticoagulation in dabigatran-treated patients presenting with acute traumatic injuries: Interim results from the RE-VERSE AD Study. British Journal of Haematology. 11-11. 2016
- Effect of Idarucizumab on Intracranial Bleeding in Dabigatran-treated Patients: Initial Results From REVERSE AD.. Stroke. 2016
- Efficacy and Safety of Dabigatran Compared With Warfarin in Patients With Atrial Fibrillation and Normal Renal Function Over Time: Insights From the RE-LY Trial. Circulation. 2015
- Exploratory Analysis of a Blood Processing Method and In-hospital Mortality. Transfusion. 23A-23A. 2015
- Exploratory Analysis of the Association Between Donor Sex and Inhospital Mortality in Transfusion Recipients. Transfusion. 23A-24A. 2015
- Quantification of Cell-free DNA in Red Blood Cell Concentrates Produced via Buffy Coat or Whole Blood-Filtered Methods. Transfusion. 9A-9A. 2015
- Initial experience with idarucizumab in dabigatran-treated patients requiring emergency surgery or interventon: interim results from the RE-VERSE AD study. European Heart Journal. 1043-1043. 2015
- Initial results of the re-verse AD trial: idarucizumab reverses the anticoagulant effects of dabigatran in patients in an emergency setting of major bleeding, urgent surgery, or interventions. Journal of Thrombosis and Haemostasis. 85-85. 2015
- Quality of vitamin k antagonist control and 1-year outcomes: a global perspective from the garfield-af registry. Journal of Thrombosis and Haemostasis. 130-130. 2015
- Quantification of cell free DNA in red blood cell concentrates produced via buffy coat (B1) OR whole blood (B2) methods. Journal of Thrombosis and Haemostasis. 468-468. 2015
- Rivaroxaban associates with factor Xa faster than apixaban: a potential explanation for their different effects on tests of coagulation. Journal of Thrombosis and Haemostasis. 556-556. 2015
- Twice-daily dosing of ASA overcomes reduced platelet response to once-daily ASA after coronary artery bypass graft surgery: a randomized controlled trial. Journal of Thrombosis and Haemostasis. 928-929. 2015
- Bleeding in Patients with Atrial Fibrillation Treated with Non Vitamin K Antagonist Oral Anticoagulants: A Population-Based Study. Blood. 343-343. 2014
- Utilization of Universal Group O Blood By Non Group O Recipients. Blood. 5103-5103. 2014
- Can Biomarkers Improve Risk Stratification of Atrial Fibrillation Patients? Analysis of 3578 Aspirin-treated Patients in ACTIVE and AVERROES. Circulation. 2014
- Genotype-Guided Vitamin K Antagonist Dosing Algorithms Improve Time in Therapeutic Range: A Systematic Review and Meta-Analysis. Circulation. 2014
- Pattern of Atrial Fibrillation and the Risk of Ischemic Stroke - A Systematic Review and Meta-Analysis. Circulation. 2014
- Stent Thrombosis and Major Bleeding With Bivalirudin versus Active Control in Patients Undergoing Percutaneous Coronary Intervention: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Circulation. 2014
- International normalized ratio control and 1-year outcomes in patients with newly diagnosed atrial fibrillation: the GARFIELD Registry. European Heart Journal. 1110-1111. 2014
- Statin use reduces incidence of adverse events in patients with atrial fibrillation in the ACTIVE-W, ACTIVE-A and AVERROES studies. European Heart Journal. 777-777. 2014
- Statin use reduces incidence of adverse events in patients with atrial fibrillation: analysis in ACTIVE-W & A and AVERROES studies. Journal of Thrombosis and Haemostasis. 7-8. 2014
- Apixaban Versus Aspirin in Atrial Fibrillation Patients >= 75 Years Old: an Analysis From the AVERROES Trial. Stroke. E187-E187. 2013
- Efficacy and Safety of Dabigatran Compared With Warfarin in Relation to Baseline Renal Function in Patients With Atrial Fibrillation - a RE-LY Trial Analysis. Circulation. 2013
- Exposure To ABO Compatible But Non-Group Identical Blood and In-Hospital Mortality. Blood. 3651-3651. 2013
- Efficacy and Safety of Different Bridging Regimens of Parenteral Anticoagulation After Mechanical Valve Replacement. Canadian Journal of Cardiology. S348-S349. 2013
- Efficacy and safety of different bridging regimens of parenteral anticoagulation after mechanical valve replacement. European Heart Journal. 814-814. 2013
- Randomized trial to examine the effect of ASA dose or ASA dosing frequency on ASA resistance after coronary artery bypass graft surgery. European Heart Journal. 22-23. 2013
- Adherence to anticoagulant treatment with dabigatran in a real-world setting. Journal of Thrombosis and Haemostasis. 954-954. 2013
- Aspirin for the prevention of recurrent venous thromboembolism (VTE): the INSPIRE collaboration. Journal of Thrombosis and Haemostasis. 338-338. 2013
- Case fatality of antithrombotic therapy associated major bleeding or major trauma. Journal of Thrombosis and Haemostasis. 417-417. 2013
- Evaluation of the Venowave (Venous-Return Assist Device) on walking distance in peripheral arterial disease. Vascular Medicine. 155-156. 2013
- Why is atrial fibrillation associated with greater mortality and disability after acute ischaemic stroke?. Journal of Neurology. S36-S36. 2013
- Stroke-Related Specific Mortality and Influencing Factors in Patients with Atrial Fibrillation in the RE-LY Trial. Stroke. 2013
- Clinical Outcomes of Patients with Previous Transient Ischaemic Attack or Stroke - a Subgroup Analysis of the Long-Term Extension of Dabigatran in Patients with Atrial Fibrillation (RELY-ABLE) Study. Cerebrovascular Diseases. 121-121. 2013
- Recurrent Events and Mortality Among Atrial Fibrillation Patients Treated with Dabigatran or Warfarin in the RE-LY Trial. Cerebrovascular Diseases. 165-165. 2013
- Aspirin for The Prevention of Recurrent Venous Thromboembolism After a First Unprovoked Event: Results of the ASPIRE Randomized Controlled Trial Abstracts. Circulation. 2777-2777. 2012
- Randomized Comparison of the Effects of Two Doses of Dabigatran Etexilate on Clinical Outcomes Over 4.3 Years: Results of the Rely-Able Double-Blind Randomized Trial. Circulation. 2793-2793. 2012
- Balancing the Benefits and Risks of Two Doses of Dabigatran Compared with Warfarin in Atrial Fibrillation. Circulation. 2012
- Dabigatran Versus Warfarin in Very Elderly Patients with Atrial Fibrillation: Results from the RE-LY Trial. Circulation. 2012
- Management and Outcomes of Major Bleeding On Dabigatran or Warfarin. Blood. 19-19. 2012
- REVERSAL OF THE ANTI-PLATELET EFFECTS OF ASPIRIN AND CLOPIDOGREL. Heart. E272.2-E272. 2012
- 504 Subtle Differences in Commercial Heparins Can Have Serious Consequences for Cardiopulmonary Bypass Patients: a randomized controlled trial. Canadian Journal of Cardiology. S285-S285. 2012
- 768 Prevalence and Predictors of Sub-Clinical Atrial Fibrillation in Pacemaker Patients. Canadian Journal of Cardiology. S394-S394. 2012
- Antiplatelet therapy offset the benefits of lowering homocysteine in patients with previous stroke or transient ischemic attack (TIA). Results of a randomised, placebo-controlled, trial. International Journal of Stroke. 17-17. 2012
- B vitamin supplementation and incidence of cancer in patients with previous stroke or transient ischemic attack (TIA): results of a randomised trial. International Journal of Stroke. 43-43. 2012
- Mortality, Blood Storage Duration, and Method of Red Cell Production: An Exploratory Analysis. Transfusion. 51A-52A. 2012
- BLEEDING WITH ASPIRIN AND APIXABAN IN PATIENTS UNSUITABLE FOR VITAMIN K ANTAGONIST THERAPY: THE AVERROES STUDY. Journal of the American College of Cardiology. E572-E572. 2012
- THE CHA2DS2-VASC SCORE IDENTIFIES AF PATIENTS WITH A CHADS2 SCORE OF 0 OR 1 TREATED WITH ANTIPLATELET THERAPY WHO ARE UNLIKELY TO BENEFIT FROM ORAL ANTICOAGULANT THERAPY. Journal of the American College of Cardiology. E570-E570. 2012
- Fibrillation atriale (FA): une exigence d’efficacité anticoagulante pour une pathologie grave. Archives des Maladies du Coeur et des Vaisseaux - Pratique. 11-12. 2012
- Impact of Treatment with Apixaban and Aspirin in Patients with Atrial Fibrillation in Relation to the CHADS2 and CHA2DS2-VASc Scores: the AVERROES Study. Circulation. 2011
- 331 Distribution of response to clopidogrel therapy using vasodilator stimulated phosphoprotein assay in patients undergoing primary percutaneous coronary intervention for ST segment elevation myocardial infarction. Canadian Journal of Cardiology. S182-S183. 2011
- Can We Do a 25,000 Patient Pragmatic Study to Address the Age of Blood and Mortality Controversy? A Pilot to Determine Feasibility. Transfusion. 193A-193A. 2011
- Apixaban in patients with atrial fibrillation and their risk for cardiovascular hospitalization: insights from the AVERROES trial. European Heart Journal. 671-671. 2011
- Dabigatran and warfarin affects the coagulation process at different levels during long-term treatment - a RELY substudy. European Heart Journal. 467-467. 2011
- Efficacy and safety of apixaban compared with aspirin in patients with atrial fibrillation who previously used and discontinued warfarin therapy: a secondary analysis of the AVERROES trial. European Heart Journal. 465-465. 2011
- Efficacy and safety of the novel oral factor Xa inhibitor apixaban in atrial fibrillation (AF) patients with chronic kidney disease (CKD): the AVERROES trial. European Heart Journal. 6-6. 2011
- Fondaparinux treatment of acute heparin-induced thrombocytopenia (HIT) confirmed by a positive serotonin-release assay (SRA plus ). Journal of Thrombosis and Haemostasis. 267-267. 2011
- No evidence of platelet activation in patients with atrial fibrillation who are treated with dabigatran: a substudy of the rely trial. Journal of Thrombosis and Haemostasis. 346-346. 2011
- Randomized comparison of the DAWN AC computer program and a simple manual nomogram for quality of warfarin dosing. Journal of Thrombosis and Haemostasis. 302-302. 2011
- AVERROES: Apixaban Versus Acetylsalicylic Acid (ASA) to Prevent Strokes. Stroke. E81-E81. 2011
- Effect of Apixaban on Covert Stroke and Cognitive Function: AVERROES MRI-Brain Assessment Trial. Stroke. E162-E162. 2011
- Apixaban in patients with atrial fibrillation and their risk for cardiovascular hospitalization: insights from the AVERROES trial. American Journal of Respiratory and Critical Care Medicine. 671-671. 2011
- D-dimer is Prognostic for Stroke, Major Bleeding and Death During Anticoagulation of Atrial Fibrillation - a RELY Substudy. Circulation. 2010
- Randomized Trial of Fondaparinux versus Heparin to Prevent Graft Failure After Coronary Artery Bypass Grafting: The Fonda CABG Pilot Study. Circulation. 2010
- Systematic Review to Identify Validated Manual Warfarin Maintenance Dosing Tools. Blood. 1554-1554. 2010
- EFFICACY AND SAFETY OF CLOPIDOGREL COMPARED WITH PLACEBO ACCORDING TO CYP2C19 GENOTYPE IN OVER 6000 PATIENTS WITH NON-ST-ELEVATION ACUTE CORONARY SYNDROMES (CURE TRIAL) AND ATRIAL FIBRILLATION (ACTIVE TRIAL). Canadian Journal of Cardiology. 146D-146D. 2010
- FIBRINOLYTIC FUNCTION IN SOUTH ASIANS AND EUROPEANS WITH CORONARY HEART DISEASE: INSIGHTS FROM THE PRACTICE REGISTRY. Canadian Journal of Cardiology. 57D-57D. 2010
- RANDOMIZED TRIAL OF FONDAPARINUX VERSUS HEPARIN TO PREVENT GRAFT FAILURE AFTER CORONARY ARTERY BYPASS GRAFTING: THE FONDA CABG PILOT STUDY. Canadian Journal of Cardiology. 114D-114D. 2010
- DABIGATRAN VERSUS WARFARIN IN ATRIAL FIBRILLATION PATIENTS WITH LOW, MODERATE AND HIGH CHADS2 SCORE: A RE-LY SUBGROUP ANALYSIS. Journal of the American College of Cardiology. 2010
- EFFECT OF AGE AND RENAL FUNCTION ON THE RISKS OF STROKE AND MAJOR BLEEDING WITH DABIGATRAN COMPARED TO WARFARIN: AN ANALYSIS FROM THE RE-LY STUDY. Journal of the American College of Cardiology. 2010
- A Meta-Analysis of Randomized Controlled Trials of Aspirin in Primary Prevention of Cardiovascular Disease.. Blood. 77-78. 2009
- Adherence with Injectibal Prophylaxis for Venous Thromboembolism (VTE) Following Total Hip (THR) and Total Knee (TKR) Replacement Surgery: Complete Registry. Blood. 233-233. 2009
- Impact of the Modified Henry Ford Warfarin Maintenance Dosing Algorithm an Quality of Anticoagulation at a Specialist Anticoagulation Clinic. Circulation. S1150-S1150. 2009
- The Effect of Ticagrelor in Stable Coronary Artery Disease Patients Nonresponsive to Clopidogrel: The RESPOND Study. Circulation. S1173-S1173. 2009
- Duration of Red Cell Storage and In-hospital Mortality in Patients with Cardiovascular Disease. Transfusion. 24A-25A. 2009
- Underuse of Evidence Based Methods for Management of Warfarin in Atrial Fibrillation Patients in Hamilton, Canada. Journal of the American College of Cardiology. A368-A368. 2009
- Low Molecular Weight Heparin Versus Fondaparinux for Thromboprophylaxis in Abdominal or Major Orthopedic Surgery Patients. American Journal of Respiratory and Critical Care Medicine. 2009
- An Indirect Comparison of the Efficacy and Safety of Factor Xa Inhibitors with Thrombin Inhibitors nn Preventing Various Thromboembolism after Hip or Knee Surgery. Circulation. S1051-S1051. 2008
- Efficacy and Safety of Clopidogrel in Acute Coronary Syndrome Patients at High Risk of Bleeding: Data from the CURE Trial. Circulation. S916-S916. 2008
- Anticoagulant intensity of enoxaparin compared with fondaparinux in the OASIS-5 trial. European Heart Journal. 746-746. 2008
- Incomplete inhibition of thromboxane biosynthesis by ASA: determinants and effect on cardiovascular risk. European Heart Journal. 404-404. 2008
- EFFECT OF FONDAPARINUX 2.5 MG ONCE DAILY ON ALL CAUSE MORTALITY: A META-ANALYSIS OF THROMBOPROPHYLAXIS TRIALS. Haematologica. 146-146. 2008
- EFFECT OF FONDAPARINUX 2.5 MG ONCE DAILY ON ALL CAUSE MORTALITY: A META-ANALYSIS OF THROMBOPROPHYLAXIS TRIALS. Haematologica. 146-146. 2008
- Development of an improved strategy for perioperative bridging of anticoagulation: Predictors of wound hematoma following surgery for permanent pacemakers and implantable defibrillators. Canadian Journal of Cardiology. 174C-174C. 2007
- Mortality and morbidity following a major bleed in a registry population with acute st elevation myocardial infarction. Canadian Journal of Cardiology. 56C-56C. 2007
- Theory to practice: Double versus triple therapy post anterior st-elevation myocardial infarction. Canadian Journal of Cardiology. 98C-98C. 2007
- Effect of fondaparinux 2.5 mg once daily on all cause mortality: a meta-analysis of thromboprophylaxis trials. European Heart Journal. 188-188. 2007
- Fondaparinux reduces symptomatic pulmonary embolism and death in patients hospitalized with congestive heart failure: a sub-analysis of the randomized ARTEMIS trial. European Heart Journal. 50-50. 2007
- Combined antiplatelet and anticoagulant therapy: clinical benefits and risks. Journal of Thrombosis and Haemostasis. 255-263. 2007
- Gastrointestinal bleeding after acute ischemic stroke: Incidence, risk factors, and clinical outcomes. Stroke. 513-513. 2007
- Platelet responsiveness to aspirin and cloidogrel and troponin increment after intervention in acute coronary lesions: results of the Practical trial. European Heart Journal. 653-653. 2006
- Adverse impact of bleeding in patients with acute coronary syndromes. Journal of the American College of Cardiology. 197A-197A. 2006
- Bleeding complications predict major cardiovascular outcomes in non ST-elevation acute coronary syndromes: Results from the OASIS-5 trial. Journal of the American College of Cardiology. 195A-195A. 2006
- Low molecular weight heparin and bleeding in patients with severe renal failure: A meta-analysis. Blood. 266A-266A. 2005
- Protein Z in ischemic stroke and its etiologic subtypes. Stroke. 292-292. 2003
- Recombinant activated factor VII for massive hemorrhage in non-hemophilia patients: The Australian experience.. Blood. 711A-711A. 2002
- Effect of direct thrombin inhibitors on reducing death and myocardial infarction in acute coronary syndromes is greater in patients undergoing percutaneous coronary intervention. Circulation. 494-494. 2002
- Inherited thrombophilia in ischemic stroke and its etiological subtypes. Stroke. 352-352. 2002
- Direct thrombin inhibitors in acute coronary syndromes: a meta-analysis based on individual patient data. European Heart Journal. 593-593. 2001
- Long-term management of unstable angina and non-Q-wave myocardial infarction. European Heart Journal, Supplement. E6-E12. 2000
- Unfractionated heparin (UFH) and low-molecular-weight heparin (LMWH) in unstable angina (USA) and Non-Q-Wave myocardial infarction (NQMI): A mete-analysis. Circulation. 621-621. 1999
- Acquired activated protein C resistance in patients with thrombosis without the factor V Q (506) mutation. Thrombosis and Haemostasis. P1305-P1305. 1997
- IMPROVED DIAGNOSIS BY FLOW-CYTOMETRY OF PREVIOUSLY UNRECOGNIZED PLATELET STORAGE POOL DEFICIENCY IN MYELOPROLIFERATIVE AND MYELODYSPLASTIC DISORDERS. Thrombosis and Haemostasis. 1061-1061. 1995
- AC losses for the prototype cable-in-conduit conductors for NET. IEEE Transactions on Magnetics. 194-197. 1992
-
journal articles
- Exploration of the regional effects of colchicine in the LoDoCo2 trial.. American Heart Journal. 278:186-194. 2024
- Letter: Incidence and Predictors of Major Gastrointestinal Bleeding in Patients on Aspirin, Low-Dose Rivaroxaban or the Combination: Secondary Analysis of the COMPASS Randomised Controlled Trial. Authors' Reply.. Alimentary Pharmacology and Therapeutics. 60:1652-1653. 2024
- Neuroglial Biomarkers for Risk Assessment of Ischemic Stroke and Other Cardiovascular Events in Patients with Atrial Fibrillation Not Receiving Oral Anticoagulation.. Journal of the American Heart Association. e038860. 2024
- Anticoagulation for Patients with Atrial Fibrillation Receiving Dialysis: A Pilot Randomized Controlled Trial.. Journal of the American Society of Nephrology. 2024
- Authors' Reply: Proton Pump Inhibitors May Cause a Decline in eGFR by Inhibiting Organic Cation Transporter 2-Dependent Creatinine Secretion.. Journal of the American Society of Nephrology. 35:1614. 2024
- A sub-study of the POISE-3 randomized trial examined effects of a perioperative hypotension-avoidance strategy versus a hypertension-avoidance strategy on the risk of acute kidney injury.. Kidney International. S0085-2538(24)00717-8. 2024
- Heart Failure Risk Assessment Using Biomarkers in Patients With Atrial Fibrillation: Analysis From COMBINE-AF.. Journal of the American College of Cardiology. 84:1528-1540. 2024
- Improving analysis of cognitive outcomes in cardiovascular trials using different statistical approaches.. Trials. 25:644. 2024
- Colchicine for secondary prevention of ischaemic stroke and atherosclerotic events: a meta-analysis of randomised trials.. EClinicalMedicine. 76:102835. 2024
- Neurofilament Light Chain and Risk of Stroke in Patients With Atrial Fibrillation. Circulation. 150:1090-1100. 2024
- Residual Stroke Risk Among Patients With Atrial Fibrillation Prescribed Oral Anticoagulants: A Patient-Level Meta-Analysis From COMBINE AF.. Journal of the American Heart Association. 13:e034758. 2024
- Design and rationale of the CLEAR SYNERGY (OASIS 9) trial: A 2x2 factorial randomized controlled trial of colchicine versus placebo and spironolactone vs placebo in patients with myocardial infarction. American Heart Journal. 275:173-182. 2024
- Health-related quality of life with rivaroxaban plus aspirin vs. aspirin alone in chronic stable cardiovascular disease: Cardiovascular Outcomes for People Using Anticoagulation Strategies (COMPASS) trial.. European Heart Journal Open. 4:oeae083. 2024
-
Incidence and predictors of major gastrointestinal bleeding in patients on aspirin, low‐dose rivaroxaban, or the combination: Secondary analysis of the
COMPASS randomised controlled trial. Alimentary Pharmacology and Therapeutics. 60:737-748. 2024 - European guidelines on peri-operative venous thromboembolism prophylaxis: first update.. European Journal of Anaesthesiology. 41:622-626. 2024
- FRAIL-AF Study: More Bleeding With DOACs Compared With VKAs in Patients With Frailty?. Canadian Journal of Cardiology. 40:1377-1378. 2024
- Optimizing antithrombotic therapy in patients with coexisting cardiovascular and gastrointestinal disease. Nature Reviews Cardiology. 21:574-592. 2024
- Perioperative management and outcomes in patients receiving low-dose rivaroxaban and/or aspirin: a subanalysis of the Cardiovascular Outcomes for People Using Anticoagulation Strategies (COMPASS) trial. Journal of Thrombosis and Haemostasis. 22:2227-2233. 2024
- Stuart J. Connolly, MD, April 9, 1949–June 2, 2024. Heart Rhythm. 21:1456-1457. 2024
- Factor XIa inhibition as a therapeutic strategy for atherothrombosis. Journal of Thrombosis and Thrombolysis. 2024
- Factor XI inhibition in cardiovascular disease. Polskie Archiwum Medycyny Wewnetrznej. 134:16799. 2024
- A Phase II randomized controlled trial evaluated antithrombotic treatment with fesomersen in patients with kidney failure on hemodialysis. Kidney International. 106:145-153. 2024
- Colchicine and Risk of Venous Thromboembolism: A Systematic Review and Meta-analysis of Randomized Controlled Trials. Canadian Journal of Cardiology. 40:1344-1346. 2024
- Outcomes of Patients with a Mechanical Heart Valve and Poor Anticoagulation Control on Warfarin. Thrombosis and Haemostasis. 124:613-624. 2024
- Restarting Anticoagulation After Major Bleeding in Patients With Atrial Fibrillation. Canadian Journal of Cardiology. 40:1291-1293. 2024
- Results of the COMPASS Trial Analyzed Using Win Ratio Compared With Conventional Analytic Approaches. Canadian Journal of Cardiology. 40:2171-2179. 2024
- Stuart J. Connolly, MD, April 9, 1949–June 2, 2024. JACC: Clinical Electrophysiology. S2405-500X(24)00562-0. 2024
- The Effects of Pantoprazole on Kidney Outcomes. Journal of the American Society of Nephrology. 35:901-909. 2024
- Impact of Frailty on the Benefits of Dual Pathway Inhibition for the Secondary Prevention of Cardiovascular Events in the COMPASS Randomised Trial. Canadian Journal of Cardiology. S0828-282X(24)00506-3. 2024
- Net clinical benefit of extended dual pathway inhibition according to baseline risk in patients with chronic coronary syndrome: a COMPASS substudy. European Heart Journal (EHJ) - Cardiovascular Pharmacotherapy. 10:201-209. 2024
- The Efficacy and Safety of Andexanet Alfa in Patients With Acute Gastrointestinal Bleeding While Taking Factor Xa Inhibitors: An ANNEXA-4 Subanalysis. Circulation. 149:1315-1318. 2024
- Urinary thromboxane and risk of cardiovascular events: role of aspirin. European Heart Journal. 45:1368-1370. 2024
- Efficacy and Safety of Non–Vitamin-K Antagonist Oral Anticoagulants Versus Warfarin Across the Spectrum of Body Mass Index and Body Weight: An Individual Patient Data Meta-Analysis of 4 Randomized Clinical Trials of Patients With Atrial Fibrillation. Circulation. 149:932-943. 2024
- Anticoagulation for mechanical aortic valves: An international survey of current practice patterns and perceptions. Thrombosis Update. 14:100164-100164. 2024
- Optimizing warfarin dosing for patients with atrial fibrillation using machine learning. Scientific Reports. 14:4516. 2024
- Bleeding Outcomes in Patients Treated With Asundexian in Phase II Trials. Journal of the American College of Cardiology. 83:669-678. 2024
- Bleeding Risk in Asian Patients. JACC Asia. 4:163-165. 2024
- Single Bolus r-SAK Before Primary PCI for ST-Segment–Elevation Myocardial Infarction. Circulation: Cardiovascular Interventions. 17:e013455. 2024
- The Cost-Effectiveness of Rivaroxaban Plus Aspirin Compared with Aspirin Alone in the COMPASS Trial: A US Perspective. American Journal of Cardiovascular Drugs. 24:117-127. 2024
- When Direct Oral Anticoagulants Should Not Be Standard Treatment. Journal of the American College of Cardiology. 83:444-465. 2024
- Effects of oral anticoagulation in people with atrial fibrillation after spontaneous intracranial haemorrhage (COCROACH): prospective, individual participant data meta-analysis of randomised trials. Lancet Neurology. 22:1140-1149. 2023
- Standard of care in advanced HIV disease: review of HIV treatment guidelines in six sub-Saharan African countries. AIDS Research and Therapy. 20:83. 2023
- Effect of colchicine on perioperative atrial fibrillation and myocardial injury after non-cardiac surgery in patients undergoing major thoracic surgery (COP-AF): an international randomised trial. The Lancet. 402:1627-1635. 2023
- Efficacy and Safety of Intensified vs Standard Prophylactic Anticoagulation Therapy in Patients Hospitalized With Coronavirus Disease 2019: Updated Systematic Review and Meta-analysis. Open Forum Infectious Diseases. 10:ofad506. 2023
- Efficacy and safety of a bolus of half-dose r-SAK prior to primary PCI in ST-elevation myocardial infarction: Rationale and design of the OPTIMA-6 trial. American Heart Journal. 265:31-39. 2023
- Factor XI Inhibitors: Potential Role in End-Stage Kidney Disease. Seminars in Nephrology. 43:151484-151484. 2023
- Warfarin faring better: vitamin K antagonists beat rivaroxaban and apixaban in the INVICTUS and PROACT Xa trials. Journal of Thrombosis and Haemostasis. 21:3067-3071. 2023
- In healthy older adults, low-dose aspirin increased incident anemia at a median 4.7 y. ACP journal club. 176:JC115-JC115. 2023
- Time to establish an international vaccine candidate pool for potential highly infectious respiratory disease: a community’s view. EClinicalMedicine. 64:102222-102222. 2023
- Could vaccinating adults against malaria materially reduce adult mortality in high-transmission areas?. Malaria Journal. 22:278. 2023
- The cost-effectiveness of rivaroxaban with or without aspirin in the COMPASS trial. European Heart Journal - Quality of Care and Clinical Outcomes. 9:502-510. 2023
- In DVT, oral DTIs and factor Xa inhibitors reduce major bleeding but not recurrent VTE vs. conventional anticoagulants. ACP journal club. 176:JC92-JC92. 2023
- P-Selectin de-ACTIVation in COVID-19: What Have We Learned?. Circulation. 148:391-393. 2023
- Testing for Hypercoagulability in Patients With Unexplained Arterial Thromboembolism. JACC Case Rep. 20:101944-101944. 2023
- Plasma angiopoietin-2 and its association with heart failure in patients with atrial fibrillation. Europace. 25:euad200. 2023
- Elevations in Creatine Kinase are Not Related to the Choice or Dose of Statins in Patients Taking Colchicine 0.5 mg Daily: Insights from the LoDoCo2 Trial. Clinical Drug Investigation. 43:575-577. 2023
- Individual net clinical outcome with oral anticoagulation in atrial fibrillation using the ABC‐AF risk scores. American Heart Journal. 261:55-63. 2023
- ACT trials: long-term outcomes. The Lancet Respiratory Medicine. 11:e50-e50. 2023
- Association of Low-Dose Colchicine With Incidence of Knee and Hip Replacements. ACP journal club. 176:737-742. 2023
- Dietary intake and cardiovascular outcomes in patients with chronic vascular disease: insights from the COMPASS trial cohort. European Journal of Preventive Cardiology (EJPC). 30:709-718. 2023
- GARFIELD-AF: risk profiles, treatment patterns and 2-year outcomes in patients with atrial fibrillation in Germany, Austria and Switzerland (DACH) compared to 32 countries in other regions worldwide. Clinical Research in Cardiology. 112:759-771. 2023
- Rivaroxaban to prevent major clinical outcomes in non-hospitalised patients with COVID-19: the CARE – COALITION VIII randomised clinical trial. EClinicalMedicine. 60:102004-102004. 2023
- Outcomes of patients with atrial fibrillation and ischemic stroke while on oral anticoagulation. European Heart Journal. 44:1807-1814. 2023
- Health status and cognitive function for risk stratification in chronic coronary and peripheral artery disease. European Journal of Preventive Cardiology (EJPC). 30:535-545. 2023
- Are P2Y12 inhibitors superior to aspirin for long-term secondary prevention of cardiovascular disease?. Expert Review of Cardiovascular Therapy. 21:305-309. 2023
- The predictive value of interarm systolic blood pressure differences in patients with vascular disease: Sub-analysis of the COMPASS trial. Atherosclerosis. 372:41-47. 2023
- Antithrombotic treatment beyond 1 year after percutaneous coronary intervention in patients with atrial fibrillation. European Heart Journal (EHJ) - Cardiovascular Pharmacotherapy. 9:208-219. 2023
- A hybrid automated event adjudication system for clinical trials. Clinical Trials. 20:166-175. 2023
- Clinical Studies with Anticoagulants that Have Changed Clinical Practice. Seminars in Thrombosis and Hemostasis. 49:242-254. 2023
- Direct Oral Anticoagulants in the Very Elderly. Thrombosis and Haemostasis. 123:377-379. 2023
- Event Adjudication Is Unnecessary in Blinded Trials and May Be Detrimental. JACC: Heart Failure. 11:422-424. 2023
- Total events and net clinical benefit of rivaroxaban and aspirin in patients with chronic coronary or peripheral artery disease: The COMPASS trial. American Heart Journal. 258:60-68. 2023
- Final Study Report of Andexanet Alfa for Major Bleeding With Factor Xa Inhibitors. Circulation. 147:1026-1038. 2023
- Conduit selection and early graft failure in coronary artery bypass surgery: A post hoc analysis of the Cardiovascular Outcomes for People Using Anticoagulation Strategies (COMPASS) coronary artery bypass grafting study. Journal of Thoracic and Cardiovascular Surgery. 165:1080-1089.e1. 2023
- Factor XI inhibitors: what should clinicians know. Current Opinion in Cardiology. 38:88-93. 2023
- Are Factor Xa Inhibitors Efficacious for Ischemic Stroke Prevention in Patients Without Atrial Fibrillation? Evidence From Randomized Clinical Trials. Canadian Journal of Cardiology. 39:187-197. 2023
- Drivers of mortality in patients with chronic coronary disease in the low-dose colchicine 2 trial. International Journal of Cardiology. 372:1-5. 2023
- Factor XI inhibitors: cardiovascular perspectives. European Heart Journal. 44:280-292. 2023
- Bone morphogenetic protein 10: a novel risk marker of ischaemic stroke in patients with atrial fibrillation. European Heart Journal. 44:208-218. 2023
- Adult malaria mortality during 2019 at Bo Government Hospital, Sierra Leone. Gates Open Research. 7:48-48. 2023
- Colchicine and diabetes in patients with chronic coronary artery disease: insights from the LoDoCo2 randomized controlled trial. Frontiers in Cardiovascular Medicine. 10:1244529. 2023
- Impact of Rabeprazole on APO-Dabigatran Exposure in Healthy Volunteers. CJC OPEN. 5:1-7. 2023
- Validating fatty acid binding protein 3 as a diagnostic and prognostic biomarker for peripheral arterial disease: a three-year prospective follow-up study. EClinicalMedicine. 55:101766-101766. 2023
- What Is the Future of Factor XI Inhibitors?. Circulation. 146:1899-1902. 2022
- Apixaban Compared With Warfarin in Patients With Atrial Fibrillation and End-Stage Renal Disease: Lessons Learned. Circulation. 146:1746-1748. 2022
- Long-Term Treatment with the Combination of Rivaroxaban and Aspirin in Patients with Chronic Coronary or Peripheral Artery Disease: Outcomes During the Open Label Extension of the COMPASS trial. European Heart Journal (EHJ) - Cardiovascular Pharmacotherapy. 8:786-795. 2022
- Colchicine and aspirin in community patients with COVID-19 (ACT): an open-label, factorial, randomised, controlled trial. The Lancet Respiratory Medicine. 10:1160-1168. 2022
- Colchicine and the combination of rivaroxaban and aspirin in patients hospitalised with COVID-19 (ACT): an open-label, factorial, randomised, controlled trial. The Lancet Respiratory Medicine. 10:1169-1177. 2022
- Rationale and design of the PeriOperative ISchemic Evaluation-3 (POISE-3): a randomized controlled trial evaluating tranexamic acid and a strategy to minimize hypotension in noncardiac surgery. Trials. 23:101. 2022
- Corrigendum to: Great Debate: Triple antithrombotic therapy in patients with atrial fibrillation undergoing coronary stenting should be limited to 1 week. European Heart Journal. 43:4634-4634. 2022
- Comparison of Investigator-Reported vs Centrally Adjudicated Major Adverse Cardiac Events. JAMA network open. 5:e2243201-e2243201. 2022
- INTERBLEED: Design of an International Study of Risk Factors for Gastrointestinal Bleeding and Cardiovascular Events After Gastrointestinal Bleeding. CJC OPEN. 4:996-1005. 2022
- The Effect of Years-Long Exposure to Low-Dose Colchicine on Renal and Liver Function and Blood Creatine Kinase Levels: Safety Insights from the Low-Dose Colchicine 2 (LoDoCo2) Trial. Clinical Drug Investigation. 42:977-985. 2022
- A Multicenter, Phase 2, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group, Dose-Finding Trial of the Oral Factor XIa Inhibitor Asundexian to Prevent Adverse Cardiovascular Outcomes After Acute Myocardial Infarction. Circulation. 146:1196-1206. 2022
- Great Debate: Triple antithrombotic therapy in patients with atrial fibrillation undergoing coronary stenting should be limited to 1 week. European Heart Journal. 43:3512-3527. 2022
- Rivaroxaban and aspirin vs. aspirin alone in Asian compared with non-Asian patients with chronic coronary artery disease or peripheral arterial disease: the COMPASS trial. European Heart Journal. 43:3542-3552. 2022
- Antiplatelet therapy in patients with atrial fibrillation: a systematic review and meta-analysis of randomized trials. European Heart Journal (EHJ) - Cardiovascular Pharmacotherapy. 8:648-659. 2022
- Impact of Insulin Receptor Substrate‐1 rs956115 and CYP2C19 rs4244285 Genotypes on Clinical Outcome of Patients Undergoing Percutaneous Coronary Intervention. Journal of the American Heart Association. 11:e025058. 2022
- Low-dose rivaroxaban plus aspirin in patients with polypharmacy and multimorbidity: an analysis from the COMPASS trial. European Heart Journal (EHJ) - Cardiovascular Pharmacotherapy. 8:462-473. 2022
- Association of body mass index with outcomes in patients with newly diagnosed atrial fibrillation: GARFIELD-AF. Open Heart. 9:e002038-e002038. 2022
- Using multimarker screening to identify biomarkers associated with cardiovascular death in patients with atrial fibrillation. Cardiovascular Research (CVR). 118:2112-2123. 2022
- Efficacy and Safety of Intensified Versus Standard Prophylactic Anticoagulation Therapy in Patients With Coronavirus Disease 2019: A Systematic Review and Meta-Analysis. Open Forum Infectious Diseases. 9:ofac285. 2022
- Efficacy and Safety Considerations With Dose-Reduced Direct Oral Anticoagulants. JAMA cardiology. 7:747-747. 2022
- Rivaroxaban 2.5 mg Twice Daily Plus Aspirin Reduces Venous Thromboembolism in Patients With Chronic Atherosclerosis. Circulation. 145:1875-1877. 2022
- Andexanet Alfa for Specific Anticoagulation Reversal in Patients with Acute Bleeding during Treatment with Edoxaban. Thrombosis and Haemostasis. 122:998-1005. 2022
- Oral anticoagulation versus antiplatelet therapy for secondary stroke prevention in patients with embolic stroke of undetermined source: A systematic review and meta-analysis. European Stroke Journal. 7:92-98. 2022
- The Anti-Coronavirus Therapies (ACT) Trials: Design, Baseline Characteristics, and Challenges. CJC OPEN. 4:568-576. 2022
- Venous and arterial thrombosis in COVID-19: An updated narrative review. Journal of Infection and Public Health. 15:689-702. 2022
- Tranexamic Acid in Patients Undergoing Noncardiac Surgery. New England Journal of Medicine. 386:1986-1997. 2022
- Low-dose rivaroxaban and aspirin among patients with peripheral artery disease: a meta-analysis of the COMPASS and VOYAGER trials. European Journal of Preventive Cardiology (EJPC). 29:e181-e189. 2022
- Inflammation as a Mechanism and Therapeutic Target in Peripheral Artery Disease. Canadian Journal of Cardiology. 38:588-600. 2022
- Efficacy and safety of low intensity vitamin K antagonists in Western and East-Asian patients with left-sided mechanical heart valves. Journal of Thrombosis and Thrombolysis. 53:697-707. 2022
- Dual antithrombotic treatment in chronic coronary syndrome: European Society of Cardiology criteria vs. CHADS-P2A2RC score. European Heart Journal. 43:996-1004. 2022
- Randomised comparative effectiveness trial of Pulmonary Embolism Prevention after hiP and kneE Replacement (PEPPER): the PEPPER trial protocol. BMJ Open. 12:e060000-e060000. 2022
- Long-Term Efficacy of Colchicine in Patients With Chronic Coronary Disease: Insights From LoDoCo2. Circulation. 145:626-628. 2022
- Advances in anticoagulation: patients with bioprosthetic heart valves. Cardiovascular Research (CVR). 118:e26-e28. 2022
- Rosuvastatin for the prevention of venous thromboembolism: a pooled analysis of the HOPE-3 and JUPITER randomized controlled trials. Cardiovascular Research (CVR). 118:897-903. 2022
- Carbamazepine, phenytoin, and oral anticoagulants: Drug‐drug interaction and clinical events in a retrospective cohort. Research and Practice in Thrombosis and Haemostasis. 6:e12650-e12650. 2022
- Direct Oral Anticoagulants Versus Warfarin in Patients With Atrial Fibrillation: Patient-Level Network Meta-Analyses of Randomized Clinical Trials With Interaction Testing by Age and Sex. Circulation. 145:242-255. 2022
- Stroke risk prediction in patients with atrial fibrillation with and without rheumatic heart disease. Cardiovascular Research (CVR). 118:295-304. 2022
- Aortic plaque burden predicts vascular events in patients with cardiovascular disease: The EAST-NOGA study. Journal of Cardiology. 79:144-152. 2022
- Dual pathway inhibition for atherosclerotic cardiovascular disease: Recent advances. Kardiologia Polska. 80:1200-1210. 2022
- Effect of a Perioperative Hypotension-Avoidance Strategy Versus a Hypertension-Avoidance Strategy on the Risk of Acute Kidney Injury: A Clinical Research Protocol for a Substudy of the POISE-3 Randomized Clinical Trial. Canadian Journal of Kidney Health and Disease. 9:205435812110692-205435812110692. 2022
- FUNCTIONAL OUTCOMES OF INDIVIDUALS WITH CARDIOVASCULAR DISEASE AFTER GASTROINTESTINAL CANCER. Journal of Cancer Rehabilitation. 5:48-55. 2022
- Intensified antiplatelet therapy in patients after percutaneous coronary intervention with high on‐treatment platelet reactivity: the OPTImal Management of Antithrombotic Agents (OPTIMA)‐2 Trial. British Journal of Haematology. 196:424-432. 2022
- Low-dose aspirin and rivaroxaban combination therapy to overcome aspirin non-sensitivity in patients with vascular disease. Frontiers in Cardiovascular Medicine. 9:912114. 2022
- Prolonged Blood Storage and Risk of Posttransfusion Acute Kidney Injury. Anesthesiology. 136:138-147. 2022
- Rivaroxaban with Aspirin Versus Aspirin for Peripheral Arterial Disease and Intermittent Claudication. Rationale and Design of the COMPASS CLAUDICATION Trial. Clinical and Applied Thrombosis/Hemostasis. 28:107602962110739-107602962110739. 2022
- Anticoagulation in patients with kidney failure on dialysis: factor XI as a therapeutic target. Kidney International. 100:1199-1207. 2021
- Effect of Colchicine vs Usual Care Alone on Intubation and 28-Day Mortality in Patients Hospitalized With COVID-19. JAMA network open. 4:e2141328-e2141328. 2021
- Pharmacodynamic effects of indobufen compared with aspirin in patients with coronary atherosclerosis. European Journal of Clinical Pharmacology. 77:1815-1823. 2021
- Quality of early evidence on the pathogenesis, diagnosis, prognosis and treatment of COVID-19. BMJ Evidence-Based Medicine. 26:302-306. 2021
- Direct oral anticoagulant dose selection: Challenging cases. Journal of Thrombosis and Haemostasis. 19:2680-2686. 2021
- Multiplex protein screening of biomarkers associated with major bleeding in patients with atrial fibrillation treated with oral anticoagulation. Journal of Thrombosis and Haemostasis. 19:2726-2737. 2021
- Cardioversion in patients with newly diagnosed non-valvular atrial fibrillation: observational study using prospectively collected registry data. The BMJ. 375:e066450-e066450. 2021
- Strategies for the prevention and treatment of bleeding in patients treated with dabigatran: an update. Expert Opinion on Drug Metabolism and Toxicology. 17:1091-1102. 2021
- Ross for Valve replacement In AduLts (REVIVAL) pilot trial: rationale and design of a randomised controlled trial. BMJ Open. 11:e046198-e046198. 2021
- Skeletonized vs Pedicled Internal Mammary Artery Graft Harvesting in Coronary Artery Bypass Surgery. JAMA cardiology. 6:1042-1042. 2021
- Corrigendum to: Efficacy and safety of low-dose colchicine in patients with coronary disease: a systematic review and meta-analysis of randomised trials. European Heart Journal. 42:3202-3202. 2021
- Hypercoagulability and thrombosis in COVID-19: a modifiable cause for mortality?. European Heart Journal. 42:3143-3145. 2021
- Clinical factors associated with peripheral artery disease in patients with documented coronary artery disease: A post hoc analysis of the COMPASS trial. Atherosclerosis. 331:38-44. 2021
- Colchicine in Patients With Chronic Coronary Disease in Relation to Prior Acute Coronary Syndrome. Journal of the American College of Cardiology. 78:859-866. 2021
- Restart of Anticoagulant Therapy and Risk of Thrombosis, Rebleeding, and Death after Factor Xa Inhibitor Reversal in Major Bleeding Patients. Thrombosis and Haemostasis. 121:1097-1106. 2021
- Risk stratification of cardiovascular complications using CHA2DS2-VASc and CHADS2 scores in chronic atherosclerotic cardiovascular disease. International Journal of Cardiology. 337:9-15. 2021
- Pleiotropic actions of factor Xa inhibition in cardiovascular prevention: mechanistic insights and implications for anti-thrombotic treatment. Cardiovascular Research (CVR). 117:2030-2044. 2021
- Letter to the editor: Colchicine and risk of non-cardiovascular death in patients with coronary artery disease: a pooled analysis underlying possible safety concerns. European Heart Journal (EHJ) - Cardiovascular Pharmacotherapy. 7:e71-e71. 2021
- Efficacy and safety of low-dose colchicine in patients with coronary disease: a systematic review and meta-analysis of randomized trials. European Heart Journal. 42:2765-2775. 2021
- Cardiovascular consequences of discontinuing low-dose rivaroxaban in people with chronic coronary or peripheral artery disease. Heart. 107:1130-1137. 2021
- Mortality Benefit of Rivaroxaban Plus Aspirin in Patients With Chronic Coronary or Peripheral Artery Disease. Journal of the American College of Cardiology. 78:14-23. 2021
- Cardiovascular Outcomes According to Polypharmacy and Drug Adherence in Patients with Atrial Fibrillation on Long-Term Anticoagulation (from the RE-LY Trial). American Journal of Cardiology. 149:27-35. 2021
- Correction. Journal of the American College of Cardiology. 77:2760-2760. 2021
- Hemostatic Efficacy and Anti-FXa (Factor Xa) Reversal With Andexanet Alfa in Intracranial Hemorrhage: ANNEXA-4 Substudy. Stroke. 52:2096-2105. 2021
- Reply. Journal of the American College of Cardiology. 77:2757-2757. 2021
- What is the role of growth-differentiation factor-15 in biomarker-based prediction of mortality in patients with atrial fibrillation?. European Journal of Internal Medicine. 88:23-24. 2021
- Urinary fatty acid binding protein 3 (uFABP3) is a potential biomarker for peripheral arterial disease. Scientific Reports. 11:11061. 2021
- Post-operative pain following cardiac implantable electronic device implantation: insights from the BRUISE CONTROL trials. Europace. 23:748-756. 2021
- Biomarker-Based Risk Prediction With the ABC-AF Scores in Patients With Atrial Fibrillation Not Receiving Oral Anticoagulation. Circulation. 143:1863-1873. 2021
- ANDEXANET ALFA FOR ACUTE BLEEDING DURING TREATMENT WITH ENOXAPARIN. Journal of the American College of Cardiology. 77:1856-1856. 2021
- Long-Term Treatment with Apixaban in Patients with Atrial Fibrillation: Outcomes during the Open-Label Extension following AVERROES. Thrombosis and Haemostasis. 121:518-528. 2021
- Recent Randomized Trials of Antithrombotic Therapy for Patients With COVID-19. Journal of the American College of Cardiology. 77:1903-1921. 2021
- Evaluation of the prognostic value of GDF-15, ABC-AF-bleeding score and ABC-AF-death score in patients with atrial fibrillation across different geographical areas. Open Heart. 8:e001471-e001471. 2021
- Individual Patient Data from the Pivotal Randomized Controlled Trials of Non-Vitamin K Antagonist Oral Anticoagulants in Patients with Atrial Fibrillation (COMBINE AF): Design and Rationale. American Heart Journal. 233:48-58. 2021
- Life and limb protection with dual anti-thrombotic pathway inhibition: COMPASS ushers in a new day in atherothrombotic risk reduction. Med. 2:233-242. 2021
- Antithrombotic Therapy in Patients With Atrial Fibrillation Treated With Oral Anticoagulation Undergoing Percutaneous Coronary Intervention. Circulation. 143:583-596. 2021
- 2020 Asian Pacific Society of Cardiology Consensus Recommendations on Antithrombotic Management for High-risk Chronic Coronary Syndrome. European Cardiology Review. 16:e26. 2021
- Direct Oral Anticoagulant Dosing in Extremes of Body Weight: Time to Revisit the Guidelines?. Thrombosis and Haemostasis. 121:118-120. 2021
- Error in Methods and Table. JAMA cardiology. 6:246-246. 2021
- Rivaroxaban Plus Aspirin in Obese and Overweight Patients With Vascular Disease in the COMPASS Trial. Journal of the American College of Cardiology. 77:511-525. 2021
- Rivaroxaban and Aspirin in Patients With Symptomatic Lower Extremity Peripheral Artery Disease:a Subanalysis of the COMPASS Randomized Clinical Trial (vol 6, pg 21, 2021). JAMA cardiology. 6:246-246. 2021
- Variations in incidence of venous thromboembolism in low-, middle-, and high-income countries. Cardiovascular Research (CVR). 117:576-584. 2021
- Bleeding Independently associated with Mortality after noncardiac Surgery (BIMS): an international prospective cohort study establishing diagnostic criteria and prognostic importance. British Journal of Anaesthesia. 126:163-171. 2021
- Elevated plasma levels of NT-proBNP in ambulatory patients with peripheral arterial disease. PLoS ONE. 16:e0253792-e0253792. 2021
- Mortality Benefit in the Compass Trial: is It Related to Superior Statistical Power Or Better Efficacy and safety?. Future Cardiology. 17:175-182. 2021
- Preoperative prediction of Bleeding Independently associated with Mortality after noncardiac Surgery (BIMS): an international prospective cohort study. British Journal of Anaesthesia. 126:172-180. 2021
- Rivaroxaban and Aspirin in Patients With Symptomatic Lower Extremity Peripheral Artery Disease. JAMA cardiology. 6:21-29. 2021
- The Indirect Consequences of the Response to the COVID-19 Pandemic. Journal of the American College of Cardiology. 77:186-188. 2021
- Screening of Multiple Biomarkers Associated With Ischemic Stroke in Atrial Fibrillation. Journal of the American Heart Association. 9:e018984. 2020
- Plasma Apixaban Levels in Patients Treated Off Label With the Lower Dose. Journal of the American College of Cardiology. 76:2906-2907. 2020
- Tranexamic acid and rosuvastatin in patients at risk of cardiovascular events after noncardiac surgery: a pilot of the POISE-3 randomized controlled trial. Pilot and Feasibility Studies. 6:104. 2020
- Colchicine in Patients with Chronic Coronary Disease. New England Journal of Medicine. 383:1838-1847. 2020
- Angiotensin-converting enzyme 2 (ACE2) levels in relation to risk factors for COVID-19 in two large cohorts of patients with atrial fibrillation. European Heart Journal. 41:4037-4046. 2020
- Direct oral anticoagulants: evidence and unresolved issues. The Lancet. 396:1767-1776. 2020
- Mortality benefits of thromboprophylaxis. The Lancet Haematology. 7:e783-e783. 2020
- Rivaroxaban for the Prevention of Major Adverse Cardiovascular Events in Patients with Coronary or Peripheral Artery Disease. Future Cardiology. 16:597-611. 2020
- Sulodexide versus Control and the Risk of Thrombotic and Hemorrhagic Events: Meta-Analysis of Randomized Trials. Seminars in Thrombosis and Hemostasis. 46:908-918. 2020
- Rivaroxaban for Prevention of Covert Brain Infarcts and Cognitive Decline. Stroke. 51:2901-2909. 2020
- A Novel Model for Prediction of Thromboembolic and Cardiovascular Events in Patients Without Atrial Fibrillation. American Journal of Cardiology. 131:40-48. 2020
- Apixaban for Stroke Prevention in Atrial Fibrillation: Why are Event Rates Higher in Clinical Practice than in Randomized Trials?—A Systematic Review. Thrombosis and Haemostasis. 120:1323-1329. 2020
- Evaluation of the Age, Biomarkers, and Clinical History–Bleeding Risk Score in Patients With Atrial Fibrillation With Combined Aspirin and Anticoagulation Therapy Enrolled in the ARISTOTLE and RE-LY Trials. JAMA network open. 3:e2015943-e2015943. 2020
- Is aspirin safer than a direct oral anticoagulant for patients with atrial fibrillation at high risk of bleeding?. European Journal of Internal Medicine. 79:25-26. 2020
- Trial Design Principles for Patients at High Bleeding Risk Undergoing PCI. Journal of the American College of Cardiology. 76:1468-1483. 2020
- Cardiovascular outcomes, bleeding risk, and achieved blood pressure in patients on long-term anticoagulation with the thrombin antagonist dabigatran or warfarin: data from the RE-LY trial. European Heart Journal. 41:2848-2859. 2020
- Oral factor Xa inhibitors and risk of subdural hematoma. Neurology. 95:e480-e487. 2020
- 2020 ACC Expert Consensus Decision Pathway on Management of Bleeding in Patients on Oral Anticoagulants. Journal of the American College of Cardiology. 76:594-622. 2020
- The COMPASS Trial. Circulation. 142:40-48. 2020
- Cardiac Tamponade During Uninterrupted Oral Anticoagulant Therapy for Catheter Ablation for Atrial Fibrillation. JACC: Clinical Electrophysiology. 6:796-798. 2020
- Pharmacological Agents Targeting Thromboinflammation in COVID-19: Review and Implications for Future Research. Thrombosis and Haemostasis. 120:1004-1024. 2020
- Role of Combination Antiplatelet and Anticoagulation Therapy in Diabetes Mellitus and Cardiovascular Disease. Circulation. 141:1841-1854. 2020
- COVID-19 and Thrombotic or Thromboembolic Disease: Implications for Prevention, Antithrombotic Therapy, and Follow-Up. Journal of the American College of Cardiology. 75:2950-2973. 2020
- Prothrombin Complex Concentrates for Intracranial Hemorrhage on Factor Xa Inhibitors. Circulation. 141:1690-1692. 2020
- Plasma Levels of Protein Z in Ischemic Stroke: A Systematic Review and Meta-Analysis. Thrombosis and Haemostasis. 120:815-822. 2020
- Rivaroxaban Plus Aspirin Versus Aspirin Alone in Patients With Prior Percutaneous Coronary Intervention (COMPASS-PCI). Circulation. 141:1141-1151. 2020
- Anticoagulation for Stroke Prevention in Patients With Atrial Fibrillation and End-Stage Renal Disease—First, Do No Harm. JAMA network open. 3:e202237-e202237. 2020
- Dual-pathway inhibition for secondary and tertiary antithrombotic prevention in cardiovascular disease. Nature Reviews Cardiology. 17:242-257. 2020
- Selection Bias, Orthopaedic Style. Journal of Bone and Joint Surgery. American volume. 102:631-633. 2020
- Lower versus Standard INR Targets in Atrial Fibrillation: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Thrombosis and Haemostasis. 120:484-494. 2020
- Optimal Prescription of the Lower Dose of Apixaban. Journal of the American College of Cardiology. 75:1156-1158. 2020
- Reply. Gastroenterology. 158:1175-1176. 2020
- Oral Anticoagulant Treatment in Patients with Atrial Fibrillation and Cancer. Thrombosis and Haemostasis. 120:194-196. 2020
- Risk factors and clinical outcomes in chronic coronary and peripheral artery disease: An analysis of the randomized, double-blind COMPASS trial. European Journal of Preventive Cardiology (EJPC). 27:296-307. 2020
- Association Between Low-Dose Rivaroxaban With or Without Aspirin and Ischemic Stroke Subtypes. JAMA Neurology. 77:43-43. 2020
- Fatty acid binding protein 3 is associated with peripheral arterial disease. JVS Vasc Sci. 1:168-175. 2020
- Reply. Gastroenterology. 158:285-286. 2020
- Estimating individual lifetime benefit and bleeding risk of adding rivaroxaban to aspirin for patients with stable cardiovascular disease: results from the COMPASS trial. European Heart Journal. 40:3771-3778a. 2019
- How Did We Get Here?: A Historical Review and Critical Analysis of Anticoagulation Therapy Following Mechanical Valve Replacement. Circulation. 140:1933-1942. 2019
- Applying contemporary antithrombotic therapy in the secondary prevention of chronic atherosclerotic cardiovascular disease. American Heart Journal. 218:100-109. 2019
- Diabetes Mellitus Is Associated With Increased Risk of Ischemic Stroke in Patients With and Without Coronary Artery Disease. Stroke. 50:3347-3354. 2019
- Fifty years of research on antithrombotic therapy: Achievements and disappointments. European Journal of Internal Medicine. 70:1-7. 2019
- The effect of low-dose colchicine in patients with stable coronary artery disease: The LoDoCo2 trial rationale, design, and baseline characteristics. American Heart Journal. 218:46-56. 2019
- Review: After PCI with DESs, long- and standard-term DAPT increase some adverse outcomes vs short-term DAPT. ACP journal club. 171:JC54-JC54. 2019
- Andexanet Alfa for Reversal of Factor Xa Inhibitors: A Critical Review of the Evidence. Future Cardiology. 15:395-404. 2019
- Bleeding and New Cancer Diagnosis in Patients With Atherosclerosis. Circulation. 140:1451-1459. 2019
- Antithrombotic treatment after coronary artery bypass graft surgery: systematic review and network meta-analysis. The BMJ. 367:l5476-l5476. 2019
- Dabigatran Reversal With Idarucizumab in Patients With Renal Impairment. Journal of the American College of Cardiology. 74:1760-1768. 2019
- Effect of Direct Oral Anticoagulants, Warfarin, and Antiplatelet Agents on Risk of Device Pocket Hematoma. Circulation: Arrhythmia and Electrophysiology. 12:e007545. 2019
- External applicability of the COMPASS trial: the Western Denmark Heart Registry. European Heart Journal (EHJ) - Cardiovascular Pharmacotherapy. 5:192-199. 2019
- Major Bleeding in Patients With Coronary or Peripheral Artery Disease Treated With Rivaroxaban Plus Aspirin. Journal of the American College of Cardiology. 74:1519-1528. 2019
- Safety of Proton Pump Inhibitors Based on a Large, Multi-Year, Randomized Trial of Patients Receiving Rivaroxaban or Aspirin. Gastroenterology. 157:682-691.e2. 2019
- Proton-pump inhibitors for the prevention of upper gastrointestinal bleeding in adults receiving antithrombotic therapy. Clinical Respiratory Journal. 2019. 2019
- How can the results of the COMPASS trial benefit patients with coronary or peripheral artery disease in Poland?. Kardiologia Polska. 77:661-669. 2019
- Defining high bleeding risk in patients undergoing percutaneous coronary intervention: a consensus document from the Academic Research Consortium for High Bleeding Risk. European Heart Journal. 40:2632-2653. 2019
- Rivaroxaban With or Without Aspirin in Patients With Heart Failure and Chronic Coronary or Peripheral Artery Disease. Circulation. 140:529-537. 2019
- Outcome Assessment by Central Adjudicators Versus Site Investigators in Stroke Trials. Stroke. 50:2187-2196. 2019
- Pantoprazole to Prevent Gastroduodenal Events in Patients Receiving Rivaroxaban and/or Aspirin in a Randomized, Double-Blind, Placebo-Controlled Trial. Gastroenterology. 157:403-412.e5. 2019
- Defining High Bleeding Risk in Patients Undergoing Percutaneous Coronary Intervention. Circulation. 140:240-261. 2019
- Illustrated State‐of‐the‐Art Capsules of the ISTH 2019 Congress in Melbourne, Australia. Research and Practice in Thrombosis and Haemostasis. 3:431-497. 2019
- Predictors of NOAC versus VKA use for stroke prevention in patients with newly diagnosed atrial fibrillation: Results from GARFIELD-AF. American Heart Journal. 213:35-46. 2019
- Pulmonary embolism: update on diagnosis and management. Medical Journal of Australia. 211:82-87. 2019
- Rivaroxaban Plus Aspirin Versus Aspirin in Relation to Vascular Risk in the COMPASS Trial. Journal of the American College of Cardiology. 73:3271-3280. 2019
- Individual Treatment Effect Estimation of 2 Doses of Dabigatran on Stroke and Major Bleeding in Atrial Fibrillation. Circulation. 139:2846-2856. 2019
- Analysis of Outcomes in Ischemic vs Nonischemic Cardiomyopathy in Patients With Atrial Fibrillation. JAMA cardiology. 4:526-526. 2019
- Deep vein thrombosis: update on diagnosis and management. Medical Journal of Australia. 210:516-524. 2019
- Monitoring Emerging Data From the COMPASS Trial of an Antithrombotic Agent. Journal of the American College of Cardiology. 73:2769-2772. 2019
- How I manage anticoagulant therapy in older individuals with atrial fibrillation or venous thromboembolism. Blood. 133:2269-2278. 2019
- Stroke prevention in AF: Of Asians and non-Asians. European Heart Journal. 40:1528-1530. 2019
- Anti-thrombotic options for secondary prevention in patients with chronic atherosclerotic vascular disease: what does COMPASS add?. European Heart Journal. 40:1466-1471. 2019
- Rationale, design and baseline characteristics of the effect of ticagrelor on health outcomes in diabetes mellitus patients Intervention study. Clinical Cardiology. 42:498-505. 2019
- Reply. Journal of the American College of Cardiology. 73:2360-2360. 2019
- Reversal of the antiplatelet effect of ticagrelor by simulated platelet transfusion. Transfusion. 59:1850-1856. 2019
- Rivaroxaban Plus Aspirin in Patients With Vascular Disease and Renal Dysfunction. Journal of the American College of Cardiology. 73:2243-2250. 2019
- Stroke prevention in patients from Latin American countries with non‐valvular atrial fibrillation: Insights from the GARFIELD‐AF registry. Clinical Cardiology. 42:553-560. 2019
- Full Study Report of Andexanet Alfa for Bleeding Associated with Factor Xa Inhibitors. New England Journal of Medicine. 380:1326-1335. 2019
- Management of Patients with Asymptomatic and Symptomatic Carotid Artery Disease: Update on Anti-Thrombotic Therapy. Thrombosis and Haemostasis. 119:576-585. 2019
- Rationale, design, and baseline participant characteristics in the MRI and cognitive substudy of the cardiovascular outcomes for people using anticoagulation strategies trial. International Journal of Stroke. 14:270-281. 2019
- Reduction in Mortality following Elective Major Hip and Knee Surgery: A Systematic Review and Meta-Analysis. Thrombosis and Haemostasis. 119:668-674. 2019
- The FAST-MI 2005-2010-2015 registries in the light of the COMPASS trial: The COMPASS criteria applied to a post-MI population. International Journal of Cardiology. 278:7-13. 2019
- Stroke Outcomes in the COMPASS Trial. Circulation. 139:1134-1145. 2019
- Rivaroxaban for Thromboprophylaxis in High-Risk Ambulatory Patients with Cancer. New England Journal of Medicine. 380:720-728. 2019
- Management and 1‐Year Outcomes of Patients With Newly Diagnosed Atrial Fibrillation and Chronic Kidney Disease: Results From the Prospective GARFIELD‐AF Registry. Journal of the American Heart Association. 8:e010510. 2019
- Antiplatelet Therapy versus Anticoagulation after Surgical Bioprosthetic Aortic Valve Replacement: A Systematic Review and Meta-Analysis. Thrombosis and Haemostasis. 119:328-339. 2019
- Characteristics and Management of Patients with Venous Thromboembolism: The GARFIELD-VTE Registry. Thrombosis and Haemostasis. 119:319-327. 2019
- Synergy of Dual Pathway Inhibition in Chronic Cardiovascular Disease. Circulation Research. 124:416-425. 2019
- The Ross procedure versus prosthetic and homograft aortic valve replacement: a systematic review and meta-analysis. European Journal of Cardio-thoracic Surgery. 55:247-255. 2019
- The association between blood donor sex and age and transfusion recipient mortality: an exploratory analysis. Transfusion. 59:482-491. 2019
- Cardiac Biomarkers and Left Ventricular Hypertrophy in Relation to Outcomes in Patients With Atrial Fibrillation: Experiences From the RE‐LY Trial. Journal of the American Heart Association. 8:e010107. 2019
- NOACs only for those who cannot tolerate a VKA: where is the evidence?. Acta Cardiologica. 74:17-20. 2019
- Blood Disorders in Patients Undergoing Transcatheter Aortic Valve Replacement. JACC: Cardiovascular Interventions. 12:1-11. 2019
- Comparison of Frequency of Ischemic Stroke in Patients With Versus Without Coronary Heart Disease and Without Atrial Fibrillation. American Journal of Cardiology. 123:153-158. 2019
- Rivaroxaban, Aspirin, or Both to Prevent Early Coronary Bypass Graft Occlusion. Journal of the American College of Cardiology. 73:121-130. 2019
- Anticoagulant-Related Nephropathy. Journal of the American Society of Nephrology. 29:2787-2793. 2018
- Patients with Peripheral Artery Disease in the COMPASS Trial. European Journal of Vascular and Endovascular Surgery. 56:772-773. 2018
- Continued vs. interrupted direct oral anticoagulants at the time of device surgery, in patients with moderate to high risk of arterial thrombo-embolic events (BRUISE CONTROL-2). European Heart Journal. 39:3973-3979. 2018
- In Vitro Reversal of the Anti-Aggregant Effect of Ticagrelor Using Untreated Platelets. Thrombosis and Haemostasis. 118:1895-1901. 2018
- Low-dose Rivaroxaban Plus Aspirin for the Prevention of Cardiovascular Events: an Evaluation of COMPASS. Future Cardiology. 14:443-453. 2018
- Response to: Unacceptable conflicts of interest (Br J Anaesth 2018; 121: 1183). British Journal of Anaesthesia. 121:1183-1184. 2018
- Risk profiles and one-year outcomes of patients with newly diagnosed atrial fibrillation in India: Insights from the GARFIELD-AF Registry. Indian Heart Journal. 70:828-835. 2018
- Impact of cost on use of non-vitamin K antagonists in atrial fibrillation patients in Ontario, Canada. Journal of Thrombosis and Thrombolysis. 46:310-315. 2018
- Quantifying immature platelets as markers of increased platelet production after coronary artery bypass grafting surgery. European Journal of Haematology. 101:362-367. 2018
- Rivaroxaban with or without aspirin for prevention of cardiovascular disease. Coronary Artery Disease. 29:361-365. 2018
- Antithrombotic Therapy in Patients With Atrial Fibrillation Treated With Oral Anticoagulation Undergoing Percutaneous Coronary Intervention. Circulation. 138:527-536. 2018
- Concomitant Oral Anticoagulant and Nonsteroidal Anti-Inflammatory Drug Therapy in Patients With Atrial Fibrillation. Journal of the American College of Cardiology. 72:255-267. 2018
- Direct Oral Anticoagulants and Myocardial Infarction. Journal of the American College of Cardiology. 72:27-28. 2018
- Dabigatran in patients with myocardial injury after non-cardiac surgery (MANAGE): an international, randomised, placebo-controlled trial. The Lancet. 391:2325-2334. 2018
- Reduced-Intensity Anticoagulation for Mechanical Aortic Valve Prostheses. Journal of the American College of Cardiology. 71:2727-2730. 2018
- International Normalized Ratio Targets for Left-Sided Mechanical Valve Replacement. Thrombosis and Haemostasis. 118:906-913. 2018
- Is there a role for pharmacokinetic/pharmacodynamic-guided dosing for novel oral anticoagulants?. American Heart Journal. 199:59-67. 2018
- Major Adverse Limb Events and Mortality in Patients With Peripheral Artery Disease. Journal of the American College of Cardiology. 71:2306-2315. 2018
- Efficacy and safety of dabigatran compared with warfarin in patients with atrial fibrillation in relation to renal function over time—A RE-LY trial analysis. American Heart Journal. 198:169-177. 2018
- Emergency care of patients receiving non-vitamin K antagonist oral anticoagulants. British Journal of Anaesthesia. 120:645-656. 2018
- Hemodynamic outcomes of the Ross procedure versus other aortic valve replacement: a systematic review and meta-analysis. Journal of Cardiovascular Surgery. 59:462-470. 2018
- Comparison of bleeding risk scores in patients with atrial fibrillation: insights from the RE‐LY trial. Journal of Internal Medicine. 283:282-292. 2018
- Design of a Randomized Placebo-Controlled Trial to Assess Dabigatran and Omeprazole in Patients with Myocardial Injury after Noncardiac Surgery (MANAGE). Canadian Journal of Cardiology. 34:295-302. 2018
- External applicability of the COMPASS trial: an analysis of the reduction of atherothrombosis for continued health (REACH) registry. European Heart Journal. 39:750-757a. 2018
- A biomarker-based risk score to predict death in patients with atrial fibrillation: the ABC (age, biomarkers, clinical history) death risk score. European Heart Journal. 39:477-485. 2018
- Characteristics of patients with atrial fibrillation prescribed antiplatelet monotherapy compared with those on anticoagulants: insights from the GARFIELD-AF registry. European Heart Journal. 39:464-473. 2018
- TO THE EDITOR REPLY. New England Journal of Medicine. 378:397-+. 2018
- Rivaroxaban with or without aspirin in patients with stable coronary artery disease: an international, randomised, double-blind, placebo-controlled trial (vol 391, pg 205, 2017). The Lancet. 391:204-204. 2018
- Atherothrombosis and Thromboembolism: Position Paper from the Second Maastricht Consensus Conference on Thrombosis. Thrombosis and Haemostasis. 118:229-250. 2018
- Dual and triple antithrombotic therapies: current patterns of practice and controversies. Kardiologia Polska. 76:937-944. 2018
- Identifying and Treating Young Patients at Risk for Cardiovascular Events. Journal of the American College of Cardiology. 71:303-305. 2018
- Risk factors for death, stroke, and bleeding in 28,628 patients from the GARFIELD-AF registry: Rationale for comprehensive management of atrial fibrillation. PLoS ONE. 13:e0191592-e0191592. 2018
- Rivaroxaban with or without aspirin in patients with stable coronary artery disease: an international, randomised, double-blind, placebo-controlled trial. The Lancet. 391:205-218. 2018
- Rivaroxaban with or without aspirin in patients with stable peripheral or carotid artery disease: an international, randomised, double-blind, placebo-controlled trial. The Lancet. 391:219-229. 2018
- The value of novel oral anticoagulants in rural Australia. Medical Journal of Australia. 208:15-16. 2018
- Why are outcomes different for registry patients enrolled prospectively and retrospectively? Insights from the global anticoagulant registry in the FIELD-Atrial Fibrillation (GARFIELD-AF). European Heart Journal - Quality of Care and Clinical Outcomes. 4:27-35. 2018
- 2017 ACC Expert Consensus Decision Pathway on Management of Bleeding in Patients on Oral Anticoagulants. Journal of the American College of Cardiology. 70:3042-3067. 2017
- Aortic valve replacement in younger patients. European Heart Journal. 38:3378-3381. 2017
- Comparison of the ecarin chromogenic assay and diluted thrombin time for quantification of dabigatran concentrations. Journal of Thrombosis and Haemostasis. 15:2377-2387. 2017
- Improved risk stratification of patients with atrial fibrillation: an integrated GARFIELD-AF tool for the prediction of mortality, stroke and bleed in patients with and without anticoagulation. BMJ Open. 7:e017157-e017157. 2017
- International trends in clinical characteristics and oral anticoagulation treatment for patients with atrial fibrillation: Results from the GARFIELD-AF, ORBIT-AF I, and ORBIT-AF II registries. American Heart Journal. 194:132-140. 2017
- A Test in Context: D-Dimer. Journal of the American College of Cardiology. 70:2411-2420. 2017
- Left atrial appendage occlusion for stroke prevention in patients with atrial fibrillation: a systematic review and network meta-analysis of randomized controlled trials. Journal of Cardiovascular Surgery. 59:128-139. 2017
- Red blood cell storage and in-hospital mortality: a secondary analysis of the INFORM randomised controlled trial. The Lancet Haematology. 4:e544-e552. 2017
- Rivaroxaban for Preventing Venous Thromboembolism in High-Risk Ambulatory Patients with Cancer: Rationale and Design of the CASSINI Trial. Thrombosis and Haemostasis. 117:2135-2145. 2017
- Rivaroxaban for Preventing Venous Thromboembolism in High-Risk Ambulatory Patients with Cancer: Rationale and Design of the CASSINI Trial.. Thrombosis and Haemostasis. 117:2135-2145. 2017
- Rivaroxaban with or without Aspirin in Stable Cardiovascular Disease. New England Journal of Medicine. 377:1319-1330. 2017
- HERDOO2 identified women at low risk for recurrence after 5 to 12 mo of anticoagulation for a first unprovoked VTE. ACP journal club. 167:JC33-JC33. 2017
- Assessing renal function in patients receiving DOACs: Cockcroft-Gault versus estimated glomerular filtration rate. Thrombosis Research. 157:165-166. 2017
- Bleeding impacting mortality after noncardiac surgery: a protocol to establish diagnostic criteria, estimate prognostic importance, and develop and validate a prediction guide in an international prospective cohort study. CMAJ open. 5:E594-E603. 2017
- Idarucizumab for Dabigatran Reversal — Full Cohort Analysis. New England Journal of Medicine. 377:431-441. 2017
- Impact of Spontaneous Extracranial Bleeding Events on Health State Utility in Patients with Atrial Fibrillation: Results from the ENGAGE AF‐TIMI 48 Trial. Journal of the American Heart Association. 6:e006703. 2017
- Growth-differentiation factor 15 and risk of major bleeding in atrial fibrillation: Insights from the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) trial. American Heart Journal. 190:94-103. 2017
- In Reply. Anesthesiology. 127:401-402. 2017
- Platelet Transfusion for Ticagrelor Reversal. Circulation: Cardiovascular Interventions. 10:e005579. 2017
- Rationale, Design and Baseline Characteristics of Participants in the C ardiovascular O utco m es for P eople Using A nticoagulation S trategie s (COMPASS) Trial. Canadian Journal of Cardiology. 33:1027-1035. 2017
- Apixaban-Calibrated Anti-FXa Activity in Relation to Outcome Events and Clinical Characteristics in Patients with Atrial Fibrillation: Results from the AVERROES Trial. TH Open. 01:e139-e145. 2017
- Effects of dabigatran according to age in atrial fibrillation. Heart. 103:1015-1023. 2017
- Trends in Perioperative Venous Thromboembolism Associated with Major Noncardiac Surgery. TH Open. 01:e82-e91. 2017
- Resuming warfarin after intracranial hemorrhage in patients with AF was linked to reduced mortality. ACP journal club. 166:JC70-JC70. 2017
- Altered preoperative coagulation and fibrinolysis are associated with myocardial injury after non-cardiac surgery. British Journal of Anaesthesia. 118:713-719. 2017
- Anticoagulation for Mechanical Heart Valves. Arteriosclerosis, Thrombosis and Vascular Biology. 37:743-745. 2017
- Laboratory Monitoring of Non–Vitamin K Antagonist Oral Anticoagulant Use in Patients With Atrial Fibrillation. JAMA cardiology. 2:566-566. 2017
- Once versus twice daily aspirin after coronary bypass surgery: a randomized trial. Journal of Thrombosis and Haemostasis. 15:889-896. 2017
- Extended-duration versus short-duration pharmacological thromboprophylaxis in acutely Ill hospitalized medical patients: a systematic review and meta-analysis of randomized controlled trials. Journal of Thrombosis and Thrombolysis. 43:291-301. 2017
- Mortality outcomes in patients transfused with fresher versus older red blood cells: a meta‐analysis. Vox Sanguinis. 112:268-278. 2017
- Choosing a particular oral anticoagulant and dose for stroke prevention in individual patients with non-valvular atrial fibrillation: part 1. European Heart Journal. 38:ehv643-ehv643. 2017
- Choosing a particular oral anticoagulant and dose for stroke prevention in individual patients with non-valvular atrial fibrillation: part 2. European Heart Journal. 38:ehw069-ehw069. 2017
- Short-Term versus Long-Term Blood Storage. New England Journal of Medicine. 376:1091-1094. 2017
- Clinical Implications of Reversal Agents for Direct Oral Anticoagulants. Future Cardiology. 13:153-159. 2017
- Impact of gender on event rates at 1 year in patients with newly diagnosed non-valvular atrial fibrillation: contemporary perspective from the GARFIELD-AF registry. BMJ Open. 7:e014579-e014579. 2017
- Evolving antithrombotic treatment patterns for patients with newly diagnosed atrial fibrillation. Heart. 103:307-314. 2017
- Is There a Role for Betrixaban to Prevent Stroke in Medically Ill Patients?. Circulation. 135:656-658. 2017
- Which Patients With Atrial Fibrillation and Chronic Kidney Disease Should Receive Anticoagulation—And With Which Anticoagulant?. Canadian Journal of Cardiology. 33:211-213. 2017
- Efficacy of prothrombin complex concentrates for the emergency reversal of dabigatran-induced anticoagulation. Critical Care. 20:115. 2016
- Perioperative Aspirin for Prevention of Venous Thromboembolism. Anesthesiology. 125:1121-1129. 2016
- Performance and Validation of a Novel Biomarker-Based Stroke Risk Score for Atrial Fibrillation. Circulation. 134:1697-1707. 2016
- Response by Weitz and Eikelboom to Letter Regarding Article, “Urgent Need to Measure Effects of Direct Oral Anticoagulants”. Circulation. 134:e498. 2016
- Effect of Short-Term vs. Long-Term Blood Storage on Mortality after Transfusion. New England Journal of Medicine. 375:1937-1945. 2016
- A Risk Assessment Tool Incorporating New Biomarkers for Cardiovascular Events in Acute Coronary Syndromes: The Organization to Assess Strategies in Ischemic Syndromes (OASIS) Risk Score. Canadian Journal of Cardiology. 32:1332-1339. 2016
- Antithrombotic Therapy in Patients With Atrial Fibrillation Undergoing Percutaneous Coronary Intervention. Circulation: Cardiovascular Interventions. 9:e004395. 2016
- Bleeding with Direct Oral Anticoagulants vs Warfarin: Clinical Experience. American Journal of Medicine. 129:S33-S40. 2016
- Bleeding with direct oral anticoagulants vs warfarin: clinical experience. American Journal of Emergency Medicine. 34:3-8. 2016
- Corrigendum to “Dabigatran in clinical practice: Contemporary overview of the evidence” [Int. J. Cardiol. 220 (2016) 417–428]. International Journal of Cardiology. 223:1074-1076. 2016
- Two-year outcomes of patients with newly diagnosed atrial fibrillation: results from GARFIELD-AF. European Heart Journal. 37:2882-2889. 2016
- Ciraparantag for enoxaparin reversal: Adding to the evidence. Thrombosis Research. 146:106-107. 2016
- Dabigatran in clinical practice: Contemporary overview of the evidence. International Journal of Cardiology. 220:417-428. 2016
- Measurement of Dabigatran Drug Levels to Manage Patients Taking Interacting Drugs: A Case Report. American Journal of Medicine. 129:e247-e248. 2016
- Quantification of Cell-Free DNA in Red Blood Cell Units in Different Whole Blood Processing Methods. Journal of Blood Transfusion. 2016:1-5. 2016
- Andexanet Alfa for Acute Major Bleeding Associated with Factor Xa Inhibitors. New England Journal of Medicine. 375:1131-1141. 2016
- Antithrombotic Treatments for Stroke Prevention in Elderly Patients With Nonvalvular Atrial Fibrillation: Drugs and Doses. Canadian Journal of Cardiology. 32:1108-1116. 2016
- Appropriate Apixaban Dosing. JAMA cardiology. 1:635-635. 2016
- Bleeding in patients with atrial fibrillation treated with dabigatran, rivaroxaban or warfarin: A retrospective population-based cohort study. European Journal of Internal Medicine. 33:55-59. 2016
- Comparison of international normalized ratio audit parameters in patients enrolled in GARFIELD‐AF and treated with vitamin K antagonists. British Journal of Haematology. 174:610-623. 2016
- Effect of apixaban on brain infarction and microbleeds: AVERROES-MRI assessment study. American Heart Journal. 178:145-150. 2016
- Genetic Determinants of Warfarin Maintenance Dose and Time in Therapeutic Treatment Range: A RE-LY Genomics Substudy. Pharmacogenomics. 17:1425-1439. 2016
- How good is aspirin for patients with acute brain ischaemia?. Nature Reviews Neurology. 12:434-435. 2016
- Urgent Need to Measure Effects of Direct Oral Anticoagulants. Circulation. 134:186-188. 2016
- Association of cardiac biomarkers with acute kidney injury after cardiac surgery: A multicenter cohort study. Journal of Thoracic and Cardiovascular Surgery. 152:245-251.e4. 2016
- Long-term evaluation of dabigatran 150 vs. 110 mg twice a day in patients with non-valvular atrial fibrillation. Europace. 18:973-978. 2016
- Nadroparin for the prevention of venous thromboembolism in nonsurgical patients: a systematic review and meta-analysis. Journal of Thrombosis and Thrombolysis. 42:90-98. 2016
- The novel biomarker-based ABC (age, biomarkers, clinical history)-bleeding risk score for patients with atrial fibrillation: a derivation and validation study. The Lancet. 387:2302-2311. 2016
- Individualizing Duration of Dual Antiplatelet Therapy After Acute Coronary Syndrome or Percutaneous Coronary Intervention. Circulation. 133:2094-2098. 2016
- Insights into myocardial infarction after noncardiac surgery in patients with a prior coronary artery stent. British Journal of Anaesthesia. 116:584-586. 2016
- Rapid reversal of haematoma expansion associated with vitamin K antagonists. Lancet Neurology. 15:535-537. 2016
- Red blood cell processing methods and in-hospital mortality: a transfusion registry cohort study. The Lancet Haematology. 3:e246-e254. 2016
- Red blood cell processing methods and in-hospital mortality: a transfusion registry cohort study. The Lancet Haematology. 3:E246-E254. 2016
- Updated Meta-Analysis of Aspirin in Primary Prevention of Cardiovascular Disease. American Journal of Medicine. 129:e35-e36. 2016
- Advances in Thrombosis and Hemostasis. Circulation Research. 118:1337-1339. 2016
- Evolving Treatments for Arterial and Venous Thrombosis. Circulation Research. 118:1409-1424. 2016
- Effectiveness and outcome of management strategies for dabigatran- or warfarin-related major bleeding events. Thrombosis Research. 140:81-88. 2016
- Trends in incidence and prevalence of hospitalization for atrial fibrillation and associated mortality in Western Australia, 1995–2010. International Journal of Cardiology. 208:19-25. 2016
- Clinically Significant Pocket Hematoma Increases Long-Term Risk of Device Infection. Journal of the American College of Cardiology. 67:1300-1308. 2016
-
Exposure to
ABO ‐nonidentical blood associated with increased in‐hospital mortality in patients with groupA blood. Transfusion. 56:550-557. 2016 - Incorporating edoxaban into the choice of anticoagulants for atrial fibrillation. Thrombosis and Haemostasis. 115:257-270. 2016
- Strategy of continued vs interrupted novel oral anticoagulant at time of device surgery in patients with moderate to high risk of arterial thromboembolic events: The BRUISE CONTROL-2 trial. American Heart Journal. 173:102-107. 2016
- Urgent surgery or procedures in patients taking dabigatran or warfarin: Analysis of perioperative outcomes from the RE-LY trial. Thrombosis Research. 139:77-81. 2016
- Enhanced TRAP-induced platelet aggregation with dabigatran — Clinical perspective. Thrombosis Research. 138:61-62. 2016
- Laboratory measurement of the direct oral anticoagulants. British Journal of Haematology. 172:315-336. 2016
- Transfusion of fresher vs older red blood cells in hospitalized patients: a systematic review and meta-analysis. Blood. 127:400-410. 2016
- Correction. Stroke. 47:e20. 2016
- D-dimer and factor VIIa in atrial fibrillation – prognostic values for cardiovascular events and effects of anticoagulation therapy. Thrombosis and Haemostasis. 115:921-930. 2016
- Dabigatran etexilate and reduction in serum apolipoprotein B. Heart. 102:57-62. 2016
- Effect of standardized perioperative dabigatran interruption on the residual anticoagulation effect at the time of surgery or procedure. Journal of Thrombosis and Haemostasis. 14:89-97. 2016
- Efficacy and safety of apixaban compared with aspirin in the elderly: a subgroup analysis from the AVERROES trial. Age and Ageing. 45:77-83. 2016
- Letter to the Editor. Journal of Intensive Care Medicine. 31:70-71. 2016
- Quality of Vitamin K Antagonist Control and 1-Year Outcomes in Patients with Atrial Fibrillation: A Global Perspective from the GARFIELD-AF Registry. PLoS ONE. 11:e0164076-e0164076. 2016
- Rationale and Design of the Informing Fresh versus Old Red Cell Management (INFORM) Trial: An International Pragmatic Randomized Trial. Transfusion Medicine Reviews. 30:25-29. 2016
- Colchicine in cardiac disease: a systematic review and meta-analysis of randomized controlled trials. BMC Cardiovascular Disorders. 15:96. 2015
- Correction to Dosage in: Antiplatelet Drugs: Antithrombotic Therapy and Prevention of Thrombosis: 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 148:1529-1529. 2015
- Idarucizumab. Circulation. 132:2412-2422. 2015
- Plasma IL-6 and IL-10 Concentrations Predict AKI and Long-Term Mortality in Adults after Cardiac Surgery. Journal of the American Society of Nephrology. 26:3123-3132. 2015
- Reply. Journal of the American College of Cardiology. 66:2682-2682. 2015
- Risk of Stent Thrombosis and Major Bleeding with Bivalirudin Compared with Active Control: A Systematic Review and Meta-analysis of Randomized Trials. Thrombosis Research. 136:1087-1098. 2015
- Evaluating coagulation tests in patients with atrial fibrillation using direct oral anticoagulants. Expert Review of Cardiovascular Therapy. 13:1213-1223. 2015
- ‘Real world’ use of non-vitamin K antagonist oral anticoagulants (NOACs): Lessons from the Dresden NOAC Registry. Thrombosis and Haemostasis. 113:1159-1161. 2015
- Early performance of a miniaturized leadless cardiac pacemaker: the Micra Transcatheter Pacing Study. European Heart Journal. 36:2510-2519. 2015
- Extracranial Systemic Embolic Events in Patients With Nonvalvular Atrial Fibrillation. Circulation. 132:796-803. 2015
- Interleukin-6 and interleukin-10 as acute kidney injury biomarkers in pediatric cardiac surgery. Pediatric Nephrology. 30:1519-1527. 2015
- Perioperative heart-type fatty acid binding protein is associated with acute kidney injury after cardiac surgery. Kidney International. 88:576-583. 2015
- Timing the First Postoperative Dose of Anticoagulants. Chest. 148:587-595. 2015
- Idarucizumab for Dabigatran Reversal. New England Journal of Medicine. 373:511-520. 2015
- A systematic review of contemporary trials of anticoagulants in orthopaedic thromboprophylaxis: suggestions for a radical reappraisal. Journal of Thrombosis and Thrombolysis. 40:231-239. 2015
- Effect of Bile Acid Sequestrants on the Risk of Cardiovascular Events. Circulation. Genomic and precision medicine. 8:618-627. 2015
- Mendelian randomization analysis supports the causal role of dysglycaemia and diabetes in the risk of coronary artery disease. European Heart Journal. 36:1454-1462. 2015
- Changes in Renal Function in Patients With Atrial Fibrillation. Journal of the American College of Cardiology. 65:2481-2493. 2015
- Real-world variability in dabigatran levels in patients with atrial fibrillation: reply. Journal of Thrombosis and Haemostasis. 13:1168-1169. 2015
- Vitamin K antagonist-experienced patients with a history of stroke/transient ischaemic attack who switched from warfarin to dabigatran increased their rate of recurrent stroke/transient ischaemic attack compared with those on warfarin. BMJ Evidence-Based Medicine. 20:117-117. 2015
- Anemia predicts thromboembolic events, bleeding complications and mortality in patients with atrial fibrillation: insights from the RE‐LY trial. Journal of Thrombosis and Haemostasis. 13:699-707. 2015
- Perioperative bridging anticoagulation during dabigatran or warfarin interruption among patients who had an elective surgery or procedure. Thrombosis and Haemostasis. 113:625-632. 2015
- Cardiac Biomarkers and Acute Kidney Injury After Cardiac Surgery. Pediatrics. 135:e945-e956. 2015
- Mechanical left atrial appendage closure was noninferior and superior to warfarin in atrial fibrillation. ACP journal club. 162:JC4-JC4. 2015
- Active metabolite concentration of clopidogrel in patients taking different doses of aspirin: results of the interaction trial. Journal of Thrombosis and Haemostasis. 13:347-352. 2015
- Corrigendum. Journal of Thrombosis and Haemostasis. 13:489-489. 2015
- Does Sex Affect Anticoagulant Use for Stroke Prevention in Nonvalvular Atrial Fibrillation?. Circulation. Cardiovascular Quality and Outcomes. 8:S12-S20. 2015
- Multiple daily doses of acetyl‐salicylic acid (ASA) overcome reduced platelet response to once‐daily ASA after coronary artery bypass graft surgery: a pilot randomized controlled trial. Journal of Thrombosis and Haemostasis. 13:448-456. 2015
- Real‐world variability in dabigatran levels in patients with atrial fibrillation. Journal of Thrombosis and Haemostasis. 13:353-359. 2015
- Exploratory studies on the age of transfused blood and in‐hospital mortality in patients with cardiovascular diagnoses. Transfusion. 55:364-372. 2015
- Risk of ischaemic stroke according to pattern of atrial fibrillation: analysis of 6563 aspirin-treated patients in ACTIVE-A and AVERROES. European Heart Journal. 36:281-288. 2015
-
d -Dimer Testing to Select Patients With a First Unprovoked Venous Thromboembolism Who Can Stop Anticoagulant Therapy. ACP journal club. 162:27-34. 2015 - Comparative efficacy and safety of anticoagulant strategies for acute coronary syndromes. Thrombosis and Haemostasis. 114:933-944. 2015
- Design and rationale for RE-VERSE AD: A phase 3 study of idarucizumab, a specific reversal agent for dabigatran. Thrombosis and Haemostasis. 114:198-205. 2015
- Efficacy and safety of cilostazol based triple antiplatelet treatment versus dual antiplatelet treatment in patients undergoing coronary stent implantation: an updated meta-analysis of the randomized controlled trials. Journal of Thrombosis and Thrombolysis. 39:23-34. 2015
- Genotype-guided versus standard vitamin K antagonist dosing algorithms in patients initiating anticoagulation. Thrombosis and Haemostasis. 114:768-777. 2015
- Intensity and Quality of Warfarin Anticoagulation in Chinese Patients. Stroke. 46:5-6. 2015
- Lack of consistency in the relationship between asymptomatic DVT detected by venography and symptomatic VTE in thromboprophylaxis trials. Thrombosis and Haemostasis. 114:1049-1057. 2015
- Management of bleeding with oral anticoagulants in patients with atrial fibrillation. Hamostaseologie. 35:351-357. 2015
- Profile of betrixaban and its potential in the prevention and treatment of venous thromboembolism. Vascular Health and Risk Management. 11:343-343. 2015
- Response.. Canadian Family Physician. 61:24-25. 2015
- Unmet Needs in Anticoagulant Therapy: Potential Role of Rivaroxaban. Cardiology Research. 6:267-277. 2015
- Well-managed warfarin is superior to NOACs Response. Canadian Family Physician. 61:24-25. 2015
- Antithrombotic Therapy After Acute Ischemic Stroke in Patients With Atrial Fibrillation. Stroke. 45:3637-3642. 2014
- Response to Letter Regarding Article, “Efficacy and Safety of Dabigatran Compared With Warfarin in Relation to Baseline Renal Function in Patients With Atrial Fibrillation: A RE-LY (Randomized Evaluation of Long-Term Anticoagulation Therapy) Trial Analysis”. Circulation. 130:e195. 2014
- Approach to the new oral anticoagulants in family practice: part 1: comparing the options.. Canadian Family Physician. 60:989-995. 2014
- Approach to the new oral anticoagulants in family practice: part 2: addressing frequently asked questions.. Canadian Family Physician. 60:997-1001. 2014
- Comparison of the effects of apixaban and rivaroxaban on prothrombin and activated partial thromboplastin times using various reagents. Journal of Thrombosis and Haemostasis. 12:1810-1815. 2014
- Dabigatran-related coagulopathy: when can we assume the effect has “worn off”?. American Journal of Emergency Medicine. 32:1433-1434. 2014
- Immature Platelet Count. Journal of the American College of Cardiology. 64:2130-2132. 2014
- Aspirin for the Prevention of Recurrent Venous Thromboembolism. Circulation. 130:1062-1071. 2014
- Response to Letter Regarding Article, “Management and Outcomes of Major Bleeding During Treatment With Dabigatran or Warfarin”. Circulation. 130:e95. 2014
- Addressing barriers to optimal oral anticoagulation use and persistence among patients with atrial fibrillation: Proceedings, Washington, DC, December 3-4, 2012. American Heart Journal. 168:239-247.e1. 2014
- Association of cyclooxygenase-2 genetic variant with cardiovascular disease. European Heart Journal. 35:2242-2248. 2014
- Response to Letter Regarding Article, “Causes of Death and Influencing Factors in Patients With Atrial Fibrillation: A Competing-Risk Analysis From the Randomized Evaluation of Long-Term Anticoagulant Therapy Study”. Circulation. 130:e85. 2014
- Loading dose vs. maintenance dose of warfarin for reinitiation after invasive procedures: a randomized trial. Journal of Thrombosis and Haemostasis. 12:1254-1259. 2014
- Switching Patients From Blinded Study Drug to Warfarin at the End of the ENGAGE AF–TIMI 48 Trial. Journal of the American College of Cardiology. 64:585-587. 2014
- Role of phenotypic and genetic testing in managing clopidogrel therapy. Blood. 124:689-699. 2014
- The mTORC Pathway in the Antiphospholipid Syndrome. New England Journal of Medicine. 371:369-371. 2014
- Efficacy and safety of apixaban compared with aspirin in patients who previously tried but failed treatment with vitamin K antagonists: results from the AVERROES trial. European Heart Journal. 35:1856-1863. 2014
- Heparin bridging in peri-procedural management of new oral anticoagulant: a bridge too far?. European Heart Journal. 35:1831-1833. 2014
- Modification of Outcomes With Aspirin or Apixaban in Relation to Female and Male Sex in Patients With Atrial Fibrillation. Stroke. 45:2127-2130. 2014
- Reply. Journal of the American College of Cardiology. 63:2885-2886. 2014
- Reply: regarding the effect of dabigatran plasma concentrations.. Journal of the American College of Cardiology. 63:2885-2886. 2014
- Rationale and design of the PeriOperative ISchemic Evaluation-2 (POISE-2) trial: An international 2 × 2 factorial randomized controlled trial of acetyl-salicylic acid vs placebo and clonidine vs placebo in patients undergoing noncardiac surgery. American Heart Journal. 167:804-809.e4. 2014
- Cluster randomized controlled trial of a simple warfarin maintenance dosing algorithm versus usual care among primary care practices. Journal of Thrombosis and Thrombolysis. 37:435-442. 2014
- Aspirin in Patients Undergoing Noncardiac Surgery. New England Journal of Medicine. 370:1494-1503. 2014
- Clonidine in Patients Undergoing Noncardiac Surgery. New England Journal of Medicine. 370:1504-1513. 2014
- Antiplatelet therapy in prevention of cardio- and venous thromboembolic events. Journal of Thrombosis and Thrombolysis. 37:362-371. 2014
- Recent Advances in Antidotes for Direct Oral Anticoagulants: Their Arrival Is Imminent. Canadian Journal of Cardiology. 30:381-384. 2014
- Stroke prevention in atrial fibrillation. Neurology: Clinical Practice. 4:96-98. 2014
- Efficacy and Safety of Dabigatran Compared With Warfarin in Relation to Baseline Renal Function in Patients With Atrial Fibrillation. Circulation. 129:961-970. 2014
- A cohort study examination of established and emerging risk factors for atrial fibrillation: the Busselton Health Study. European Journal of Epidemiology (EJE). 29:181-190. 2014
- Colchicine for Secondary Prevention of Cardiovascular Disease. Current Atherosclerosis Reports. 16:391. 2014
- Dabigatran versus warfarin in patients with mechanical heart valves: reply. Journal of Thrombosis and Haemostasis. 12:426-426. 2014
- Myocardial Injury after Noncardiac Surgery. Anesthesiology. 120:564-578. 2014
- Review: New oral anticoagulants increase GI bleeding in venous thrombosis and ACS. ACP journal club. 160:JC4-JC4. 2014
- Efficacy and Safety of Warfarin VS. Antiplatelet Therapy in Patients with Systolic Heart Failure and Sinus Rhythm: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. International Journal of Stroke. 9:199-206. 2014
- The Effect of Dabigatran Plasma Concentrations and Patient Characteristics on the Frequency of Ischemic Stroke and Major Bleeding in Atrial Fibrillation Patients. Journal of the American College of Cardiology. 63:321-328. 2014
- Dabigatran in Patients with Mechanical Heart Valves. New England Journal of Medicine. 370:381-384. 2014
- Accelerated care versus standard care among patients with hip fracture: the HIP ATTACK pilot trial. CANADIAN MEDICAL ASSOCIATION JOURNAL. 186:E52-E60. 2014
- Betrixaban (PRT054021): pharmacology, Dose Selection and Clinical Studies. Future Cardiology. 10:43-52. 2014
- Efficacy and safety of early parenteral anticoagulation as a bridge to warfarin after mechanical valve replacement. Thrombosis and Haemostasis. 112:1120-1128. 2014
- Extended‐duration new oral anticoagulants for venous thromboprophylaxis in patients undergoing total hip arthroplasty: a meta‐analysis of the randomized controlled trials. Journal of Thrombosis and Haemostasis. 12:107-109. 2014
- Mandatory contrast-enhanced venography to detect deep-vein thrombosis (DVT) in studies of DVT prophylaxis: upsides and downsides. Thrombosis and Haemostasis. 111:10-13. 2014
- New oral anticoagulants for stroke prevention in atrial fibrillation: impact of study design, double counting and unexpected findings on interpretation of study results and conclusions. Thrombosis and Haemostasis. 112:798-807. 2014
- Novel Oral Anticoagulants: A Focused Review for Stroke Physicians. International Journal of Stroke. 9:71-78. 2014
- Organ-specific bleeding patterns of anticoagulant therapy: lessons from clinical trials. Thrombosis and Haemostasis. 112:918-923. 2014
- Prevention of thromboembolism in the patient with acute coronary syndrome and atrial fibrillation. Current Opinion in Cardiology. 29:1-9. 2014
- Shorter or longer anticoagulation to prevent recurrent venous thromboembolism: systematic review and meta-analysis. BMJ Open. 4:e005674-e005674. 2014
- Systematic Review of Observational Studies Assessing Bleeding Risk in Patients with Atrial Fibrillation Not Using Anticoagulants. PLoS ONE. 9:e88131-e88131. 2014
- Targeting Cholesterol Crystal-Induced Inflammation for the Secondary Prevention of Cardiovascular Disease. Journal of Cardiovascular Pharmacology and Therapeutics. 19:45-52. 2014
- Anticoagulation in Patients Aged ≥75 years with Atrial Fibrillation: Role of Novel Oral Anticoagulants. Cardiology and Therapy. 2:135-149. 2013
- Direct-Acting Oral Anticoagulants. JAMA Neurology. 70:1483-1484. 2013
- The effect of homocysteine-lowering with B-vitamins on osteoporotic fractures in patients with cerebrovascular disease: substudy of VITATOPS, a randomised placebo-controlled trial. BMC Geriatrics. 13:88. 2013
- Edoxaban versus Warfarin in Patients with Atrial Fibrillation. New England Journal of Medicine. 369:2093-2104. 2013
- Management and Outcomes of Major Bleeding During Treatment With Dabigatran or Warfarin. Circulation. 128:2325-2332. 2013
- Stroke prevention in older adults with atrial fibrillation. CANADIAN MEDICAL ASSOCIATION JOURNAL. 185:1479-1480. 2013
- Causes of Death and Influencing Factors in Patients With Atrial Fibrillation. Circulation. 128:2192-2201. 2013
- Dabigatran versus Warfarin in Patients with Mechanical Heart Valves. New England Journal of Medicine. 369:1206-1214. 2013
- Four-Factor Prothrombin Complex Concentrate for Urgent Reversal of Vitamin K Antagonists in Patients With Major Bleeding. Circulation. 128:1179-1181. 2013
- Antiplatelet Therapy and Cardiac Surgery: Review of Recent Evidence and Clinical Implications. Canadian Journal of Cardiology. 29:1042-1047. 2013
- Balancing the Benefits and Risks of 2 Doses of Dabigatran Compared With Warfarin in Atrial Fibrillation. Journal of the American College of Cardiology. 62:900-908. 2013
- Bleeding Risk in Atrial Fibrillation Patients Taking Vitamin K Antagonists: Systematic Review and Meta-Analysis. Clinical Pharmacology and Therapeutics. 94:367-375. 2013
- The effects of apixaban on hospitalizations in patients with different types of atrial fibrillation: insights from the AVERROES trial. European Heart Journal. 34:2752-2759. 2013
- Association of atrial fibrillation with mortality and disability after ischemic stroke. Neurology. 81:825-832. 2013
- Effect of B Vitamins and Lowering Homocysteine on Cognitive Impairment in Patients With Previous Stroke or Transient Ischemic Attack. Stroke. 44:2232-2239. 2013
- Novel Oral Anticoagulants for Atrial Fibrillation. Current Atherosclerosis Reports. 15:344. 2013
- Targeting the Unstable Plaque in Acute Coronary Syndromes. Clinical Therapeutics. 35:1099-1107. 2013
- The Long-Term Multicenter Observational Study of Dabigatran Treatment in Patients With Atrial Fibrillation (RELY-ABLE) Study. Circulation. 128:237-243. 2013
- Adherence to anticoagulant treatment with dabigatran in a real‐world setting. Journal of Thrombosis and Haemostasis. 11:1295-1299. 2013
- Assessment of Anticoagulation Intensity and Management of Bleeding With Old and New Oral Anticoagulants. Canadian Journal of Cardiology. 29:S34-S44. 2013
- Processed residual pump blood in cardiac surgery: the Processed Residual Blood in Cardiac surgery trial. Transfusion. 53:1487-1492. 2013
- Stroke Prevention in Atrial Fibrillation Patients With Chronic Kidney Disease. Canadian Journal of Cardiology. 29:S71-S78. 2013
- Anticoagulant therapy in acute brain ischaemia. Lancet Neurology. 12:526-527. 2013
- New oral anticoagulants in elderly patients. Best Practice and Research in Clinical Haematology. 26:215-224. 2013
- Betrixaban compared with warfarin in patients with atrial fibrillation: results of a phase 2, randomized, dose-ranging study (Explore-Xa). European Heart Journal. 34:1498-1505. 2013
- Atrial fibrillation is associated with increased mortality: causation or association?. European Heart Journal. 34:1027-1030. 2013
- Genetic Determinants of Dabigatran Plasma Levels and Their Relation to Bleeding. Circulation. 127:1404-1412. 2013
- Anticoagulation management in patients with mechanical heart valves having pacemaker or defibrillator insertion. Thrombosis Research. 131:300-303. 2013
- Is there really misuse and abuse of dabigatran?. Medical Journal of Australia. 198:358-359. 2013
- Venous thromboembolism prophylaxis: do trial results enable clinicians and patients to evaluate whether the benefits justify the risk? Proceedings of an Ad Hoc Working Group Meeting. Journal of Thrombosis and Haemostasis. 11:778-782. 2013
- Aspirin did not reduce recurrence after a first-ever, unprovoked venous thromboembolism. ACP journal club. 158:JC2-JC2. 2013
- Response to Letters Regarding Article, “Periprocedural Bleeding and Thromboembolic Events With Dabigatran Compared With Warfarin: Results From the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) Randomized Trial”. Circulation. 127:E506-E506. 2013
- Response to letters regarding article, “Periprocedural bleeding and thromboembolic events with dabigatran compared with warfarin: results from the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) Randomized Trial”.. Circulation. 127:e506. 2013
- Aspirin for Preventing Venous Thromboembolism. New England Journal of Medicine. 368:772-773. 2013
- Aspirin for preventing venous thromboembolism.. New England Journal of Medicine. 368:772. 2013
- Aspirin for preventing venous thromboembolism.. New England Journal of Medicine. 368:773. 2013
- Concomitant Use of Antiplatelet Therapy with Dabigatran or Warfarin in the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) Trial. Circulation. 127:634-640. 2013
- Anti‐PF4/heparin antibodies and venous graft occlusion in postcoronary artery bypass surgery patients randomized to postoperative unfractionated heparin or fondaparinux thromboprophylaxis. Journal of Thrombosis and Haemostasis. 11:253-260. 2013
- Dabigatran attenuates thrombin generation to a lesser extent than warfarin: could this explain their differential effects on intracranial hemorrhage and myocardial infarction?. Journal of Thrombosis and Thrombolysis. 35:295-301. 2013
- Modification of Outcomes With Aspirin or Apixaban in Relation to CHADS 2 and CHA 2 DS 2 -VASc Scores in Patients With Atrial Fibrillation. Circulation: Arrhythmia and Electrophysiology. 6:31-38. 2013
- Pacemaker-Detected Atrial Fibrillation in Patients With Pacemakers: Prevalence, Predictors, and Current Use of Oral Anticoagulation. Canadian Journal of Cardiology. 29:224-228. 2013
- The CHA2DS2-VASc score identifies those patients with atrial fibrillation and a CHADS2 score of 1 who are unlikely to benefit from oral anticoagulant therapy. European Heart Journal. 34:170-176. 2013
- A guide to GRADE guidelines for the readers of JTH. Journal of Thrombosis and Haemostasis. 11:1603-1608. 2013
- A response to–There’s madness in their methods. Journal of Thrombosis and Haemostasis. 11:785-786. 2013
- Dabigatran monitoring made simple?. Thrombosis and Haemostasis. 110:393-395. 2013
- Erratum to: Relation between clopidogrel active metabolite levels and different platelet aggregation methods in patients receiving clopidogrel and aspirin. Journal of Thrombosis and Thrombolysis. 35:130-130. 2013
- Low-Dose Colchicine for Secondary Prevention of Cardiovascular Disease. Journal of the American College of Cardiology. 61:404-410. 2013
- Procoagulants for management of bleeding with the new oral anticoagulants. Thrombosis and Haemostasis. 110:01-01. 2013
- Antithrombotic therapy for stroke prevention in non-valvular atrial fibrillation. Lancet Neurology. 11:1066-1081. 2012
- B Vitamins and Magnetic Resonance Imaging–Detected Ischemic Brain Lesions in Patients With Recent Transient Ischemic Attack or Stroke. Stroke. 43:3266-3270. 2012
- Bleeding During Treatment With Aspirin Versus Apixaban in Patients With Atrial Fibrillation Unsuitable for Warfarin. Stroke. 43:3291-3297. 2012
- Sex, Stroke, and Atrial Fibrillation. JAMA Neurology. 69:1641-1641. 2012
- Low-Dose Aspirin for Preventing Recurrent Venous Thromboembolism. New England Journal of Medicine. 367:1979-1987. 2012
- Periprocedural Management and Approach to Bleeding in Patients Taking Dabigatran. Circulation. 126:2428-2432. 2012
- Variation in Warfarin Dose Adjustment Practice Is Responsible for Differences in the Quality of Anticoagulation Control Between Centers and Countries. Circulation. 126:2309-2316. 2012
- Anticoagulants in Patients with Atrial Fibrillation and End-Stage Renal Disease. Postgraduate Medicine. 124:17-25. 2012
- Relation between clopidogrel active metabolite levels and different platelet aggregation methods in patients receiving clopidogrel and aspirin. Journal of Thrombosis and Thrombolysis. 34:429-436. 2012
- Anticoagulants in atrial fibrillation patients with chronic kidney disease. Nature Reviews Nephrology. 8:569-578. 2012
- Subtle differences in commercial heparins can have serious consequences for cardiopulmonary bypass patients: A randomized controlled trial. Journal of Thoracic and Cardiovascular Surgery. 144:944-950.e3. 2012
- Translational Success Stories. Circulation Research. 111:920-929. 2012
- Prevention of Thromboembolic Events After Bioprosthetic Aortic Valve Replacement. Journal of the American College of Cardiology. 60:978-980. 2012
- The aspirin controversy in primary prevention. Current Opinion in Cardiology. 27:499-507. 2012
- The relationship between CYP2C19 polymorphisms and ischaemic and bleeding outcomes in stable outpatients: the CHARISMA genetics study. European Heart Journal. 33:2143-2150. 2012
- Antithrombotic Therapy After Coronary Artery Stenting in Patients With Atrial Fibrillation. Circulation: Cardiovascular Interventions. 5:454-455. 2012
- Aspirin response variability after major orthopedic surgery. Thrombosis Research. 130:216-220. 2012
- Rivaroxaban for stroke prevention in atrial fibrillation: a critical review of the ROCKET AF trial. Expert Review of Cardiovascular Therapy. 10:965-972. 2012
- Stroke Risk and Efficacy of Apixaban in Atrial Fibrillation Patients with Moderate Chronic Kidney Disease. Journal of Stroke and Cerebrovascular Diseases. 21:429-435. 2012
- The hazards of interrupting anticoagulation therapy in atrial fibrillation. European Heart Journal. 33:1864-1866. 2012
- Which Risk Factors Are More Associated With Ischemic Stroke Than Intracerebral Hemorrhage in Patients With Atrial Fibrillation?. Stroke. 43:2048-2054. 2012
- Periprocedural Bleeding and Thromboembolic Events With Dabigatran Compared With Warfarin. Circulation. 126:343-348. 2012
- Direct thrombin inhibitors in cardiovascular disease. Nature Reviews Cardiology. 9:402-414. 2012
- Randomized controlled trials of new oral anticoagulants for stroke prevention in atrial fibrillation. Current Opinion in Cardiology. 27:331-339. 2012
- Error in Viewpoint in: Statin Therapy for Healthy Men Identified as ‘Increased Risk,’. Journal of the American Medical Association (JAMA). 307:2590-2590. 2012
- A comparison of dabigatran etexilate with warfarin in patients with mechanical heart valves: The Randomized, phase II study to Evaluate the sAfety and pharmacokinetics of oraL dabIGatran etexilate in patients after heart valve replacemeNt (RE-ALIGN). American Heart Journal. 163:931-937.e1. 2012
- Antiplatelet therapy and the effects of B vitamins in patients with previous stroke or transient ischaemic attack: a post-hoc subanalysis of VITATOPS, a randomised, placebo-controlled trial. Lancet Neurology. 11:512-520. 2012
- Old blood bad? Either the biggest issue in transfusion medicine or a nonevent. Transfusion. 52:1165-1167. 2012
- Quality of individual INR control and the risk of stroke and bleeding events in atrial fibrillation patients: A nested case control analysis of the ACTIVE W study. Thrombosis Research. 129:715-719. 2012
- Reducing the risk of recurrent stroke in patients with AF. Lancet Neurology. 11:479-481. 2012
- The effect of blood storage duration on in‐hospital mortality: a randomized controlled pilot feasibility trial. Transfusion. 52:1203-1212. 2012
- The role of comparative effectiveness research in transfusion medicine clinical trials: proceedings of a National Heart, Lung, and Blood Institute workshop. Transfusion. 52:1363-1378. 2012
- Treatment With B Vitamins and Incidence of Cancer in Patients With Previous Stroke or Transient Ischemic Attack. Stroke. 43:1572-1577. 2012
- Warfarin in Heart Failure. New England Journal of Medicine. 366:1936-1938. 2012
- Antithrombotic therapy for stroke prevention in atrial fibrillation and mechanical heart valves. American Journal of Hematology. 87:S100-S107. 2012
- Dabigatran and risk of myocardial infarction. Nature Reviews Cardiology. 9:260-262. 2012
- Dabigatran efficacy‐safety assessment for stroke prevention in patients with atrial fibrillation. Journal of Thrombosis and Haemostasis. 10:966-968. 2012
- Letter by Van de Werf et al Regarding Article, “Using Dabigatran in Patients With Stroke: A Practical Guide for Clinicians”. Stroke. 43:e46-e47. 2012
- Effect of PON1 Q192R Genetic Polymorphism on Clopidogrel Efficacy and Cardiovascular Events in the Clopidogrel in the Unstable Angina to Prevent Recurrent Events Trial and the Atrial Fibrillation Clopidogrel Trial With Irbesartan for Prevention of Vascular Events. Circulation. Genomic and precision medicine. 5:250-256. 2012
- Reversal of the anti‐platelet effects of aspirin and clopidogrel. Journal of Thrombosis and Haemostasis. 10:521-528. 2012
- Aspirin. Circulation. 125:e439-e442. 2012
- Apixaban versus aspirin in patients with atrial fibrillation and previous stroke or transient ischaemic attack: a predefined subgroup analysis from AVERROES, a randomised trial. Lancet Neurology. 11:225-231. 2012
- More on Acutely Injured Patients Receiving Dabigatran. New England Journal of Medicine. 366:863-864. 2012
- Recombinant factor VIIa (rFVIIa) and hemodialysis to manage massive dabigatran-associated postcardiac surgery bleeding. Blood. 119:2172-2174. 2012
- Myocardial Ischemic Events in Patients With Atrial Fibrillation Treated With Dabigatran or Warfarin in the RE-LY (Randomized Evaluation of Long-Term Anticoagulation Therapy) Trial. Circulation. 125:669-676. 2012
- Antiplatelet Drugs. Chest. 141:e89S-e119S. 2012
- Dabigatran for patients with a mechanical valve. Heart Lung and Circulation. 21:121-121. 2012
- New Antithrombotic Drugs. Chest. 141:e120S-e151S. 2012
- Preventing Cardioembolic Stroke in Atrial Fibrillation with Dabigatran. Current Neurology and Neuroscience Reports. 12:17-23. 2012
- Randomized controlled trial of a new portable calf compression device (Venowave) for prevention of venous thrombosis in high‐risk neurosurgical patients. Journal of Thrombosis and Haemostasis. 10:229-235. 2012
- The King is Dead (Warfarin): Direct Thrombin and Factor Xa Inhibitors: The Next Diadochian War?. International Journal of Stroke. 7:139-141. 2012
- The reemergence of aspirin for the prevention of venous thromboembolism.. Clinical Advances in Hematology and Oncology. 10:120-121. 2012
- Reply to Letters Regarding Article, “Risk of Bleeding With 2 Doses of Dabigatran Compared With Warfarin in Older and Younger Patients With Atrial Fibrillation: An Analysis of the Randomized Evaluation of Long-Term Anticoagulant Therapy (RE-LY) Trial”. Circulation. 125:E293-E294. 2012
- Approach to outcome measurement in the prevention of thrombosis in surgical and medical patients: Antithrombotic Therapy and Prevention of Thrombosis: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 141:e185S-e194S. 2012
- Effect of colchicine compared with placebo on high sensitivity C-reactive protein in patients with acute coronary syndrome or acute stroke: a pilot randomized controlled trial. Journal of Thrombosis and Thrombolysis. 33:88-94. 2012
- Idrabiotaparinux treatment for venous thromboembolism. The Lancet. 379:96-98. 2012
- Methodology for the development of antithrombotic therapy and prevention of thrombosis guidelines: Antithrombotic Therapy and Prevention of Thrombosis: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 141:53S-70S. 2012
- Prognostic importance of preoperative anti-PF4/heparin antibodies in patients undergoing cardiac surgery. Thrombosis and Haemostasis. 107:8-14. 2012
- Randomised comparison of a simple warfarin dosing algorithm versus a computerised anticoagulation management system for control of warfarin maintenance therapy. Thrombosis and Haemostasis. 108:1228-1235. 2012
- Should Warfarin Be Restarted After Warfarin-Associated Intracranial Hemorrhage?. Canadian Journal of Cardiology. 28:6-8. 2012
- Stroke prevention in elderly patients with atrial fibrillation: challenges for anticoagulation. Journal of Internal Medicine. 271:15-24. 2012
- The serological profile of early-onset and persisting post-cardiac surgery thrombocytopenia complicated by “true” heparin-induced thrombocytopenia. Thrombosis and Haemostasis. 107:998-1000. 2012
- Fondaparinux treatment of acute heparin‐induced thrombocytopenia confirmed by the serotonin‐release assay: a 30‐month, 16‐patient case series. Journal of Thrombosis and Haemostasis. 9:2389-2396. 2011
- Risks for Stroke, Bleeding, and Death in Patients With Atrial Fibrillation Receiving Dabigatran or Warfarin in Relation to the CHADS_2 Score: A Subgroup Analysis of the RE-LY Trial. ACP journal club. 155:660-660. 2011
- Net Clinical Benefit of Adding Clopidogrel to Aspirin Therapy in Patients With Atrial Fibrillation for Whom Vitamin K Antagonists Are Unsuitable. ACP journal club. 155:579-579. 2011
- Use of Clopidogrel Post-Coronary Artery Bypass Surgery in Canadian Patients With Acute Coronary Syndromes. Canadian Journal of Cardiology. 27:711-715. 2011
- CYP2C19 Genetic Testing Should Not Be Done in All Patients Treated With Clopidogrel Who Are Undergoing Percutaneous Coronary Intervention. Circulation: Cardiovascular Interventions. 4:514-521. 2011
- Antithrombotic Therapy in Patients With Atrial Fibrillation Undergoing Coronary Stenting. Circulation: Cardiovascular Interventions. 4:522-534. 2011
- Apixaban in Acute Coronary Syndromes. Cardiovascular Therapeutics. 29:285-290. 2011
- Current Evidence for Genetic Testing in Clopidogrel-Treated Patients Undergoing Coronary Stenting. Circulation: Cardiovascular Interventions. 4:505-513. 2011
- Randomized trial of fondaparinux versus heparin to prevent graft failure after coronary artery bypass grafting: the Fonda CABG study. Journal of Thrombosis and Thrombolysis. 32:378-385. 2011
-
Is it possible to define resistance to acetylsalicylic acid and P2Y
12 blockers at the patient's bedside?. Dialogues in Cardiovascular Medicine. 16:21-48. 2011 - Implications of variability in definition and reporting of major bleeding in randomized trials of oral P2Y12 inhibitors for acute coronary syndromes. European Heart Journal. 32:2256-2265. 2011
- New Anticoagulants for Atrial Fibrillation: The Beginning of a A New Era in Stroke Prevention. Canadian Journal of Neurological Sciences. 38:777-782. 2011
- Importance of Family History as a Risk Factor for Venous Thromboembolism. Circulation. 124:996-997. 2011
- Bleeding in acute coronary syndromes and percutaneous coronary interventions: position paper by the Working Group on Thrombosis of the European Society of Cardiology. European Heart Journal. 32:1854-1864. 2011
- Overexpression of the Multidrug Resistance Protein-4 Transporter in Patients Undergoing Coronary Artery Bypass Graft Surgery. Journal of the American College of Cardiology. 58:762-764. 2011
- Should adult patients be routinely tested for heritable thrombophilia after an episode of venous thromboembolism?. Medical Journal of Australia. 195:139-142. 2011
- Chills and limb pain following administration of low‐molecular‐weight heparin for treatment of acute venous thromboembolism. American Journal of Hematology. 86:603-606. 2011
- Effect of Aspirin on Mortality in the Primary Prevention of Cardiovascular Disease. American Journal of Medicine. 124:621-629. 2011
- Apixaban in Patients with Atrial Fibrillation REPLY. New England Journal of Medicine. 364:2363-2364. 2011
- The authors reply. New England Journal of Medicine. 364:2363-2364. 2011
- Standardized Bleeding Definitions for Cardiovascular Clinical Trials. Circulation. 123:2736-2747. 2011
- Risk of Bleeding With 2 Doses of Dabigatran Compared With Warfarin in Older and Younger Patients With Atrial Fibrillation. Circulation. 123:2363-2372. 2011
- Effectiveness and safety of combined antiplatelet and anticoagulant therapy: A critical review of the evidence from randomized controlled trials. Blood Reviews. 25:123-129. 2011
- Dabigatran Etexilate. Circulation. 123:1436-1450. 2011
- Apixaban in Patients with Atrial Fibrillation. New England Journal of Medicine. 364:806-817. 2011
- Dabigatran for stroke prevention in atrial fibrillation: the RE-LY trial. Expert Review of Cardiovascular Therapy. 9:279-286. 2011
- Novel Oral Factor Xa and Thrombin Inhibitors in the Management of Thromboembolism. Annual Review of Medicine. 62:41-57. 2011
- CYP2C19 Genotype and Outcomes of Clopidogrel Treatment REPLY. New England Journal of Medicine. 364:482-482. 2011
- Endometriosis-Associated Ovarian Carcinomas. New England Journal of Medicine. 364:482-485. 2011
- New oral anticoagulants for thromboprophylaxis in patients having hip or knee arthroplasty. The BMJ. 342:c7270-c7270. 2011
- Therapeutics New oral anticoagulants for thromboprophylaxis in patients having hip or knee arthroplasty. The BMJ. 342. 2011
- Consensus Document: Antithrombotic therapy in patients with atrial fibrillation undergoing coronary stenting. Thrombosis and Haemostasis. 106:571-584. 2011
- Double-dose clopidogrel in patients undergoing PCI for ACS – Authors' reply. The Lancet. 377:298-298. 2011
- Validity of Composite Outcomes in Meta-Analyses of Stroke Prevention Trials: The Case of Aspirin. Cerebrovascular Diseases. 32:22-27. 2011
- Dosing of Clopidogrel and Aspirin in Acute Coronary Syndromes REPLY. New England Journal of Medicine. 363:2467-2468. 2010
- The authors reply. New England Journal of Medicine. 363:2467-2468. 2010
- Efficacy and safety of fondaparinux in patients with ST-segment elevation myocardial infarction across the age spectrum. Results from the Organization for the Assessment of Strategies for Ischemic Syndromes 6 (OASIS-6) trial. American Heart Journal. 160:1049-1055. 2010
- Randomized trial of aspirin and clopidogrel versus aspirin alone for the prevention of coronary artery bypass graft occlusion: the Preoperative Aspirin and Postoperative Antiplatelets in Coronary Artery Bypass Grafting study. American Heart Journal. 160:1178-1184. 2010
- Mortality and morbidity following a major bleed in a registry population with acute ST elevation myocardial infarction. Journal of Thrombosis and Thrombolysis. 30:434-440. 2010
- Effects ofCYP2C19Genotype on Outcomes of Clopidogrel Treatment. New England Journal of Medicine. 363:1704-1714. 2010
- Double-dose versus standard-dose clopidogrel and high-dose versus low-dose aspirin in individuals undergoing percutaneous coronary intervention for acute coronary syndromes (CURRENT-OASIS 7): a randomised factorial trial. The Lancet. 376:1233-1243. 2010
- The Use of Platelet Function Assays May Help to Determine Appropriate Antiplatelet Treatment Options in a Patient With Recurrent Stroke on Baby Aspirin. Stroke. 41:2398-2399. 2010
- Dose Comparisons of Clopidogrel and Aspirin in Acute Coronary Syndromes. New England Journal of Medicine. 363:930-942. 2010
- A critical appraisal of bleeding events reported in venous thromboembolism prevention trials of patients undergoing hip and knee arthroplasty. Journal of Thrombosis and Haemostasis. 8:1966-1975. 2010
- B vitamins in patients with recent transient ischaemic attack or stroke in the VITAmins TO Prevent Stroke (VITATOPS) trial: a randomised, double-blind, parallel, placebo-controlled trial. Lancet Neurology. 9:855-865. 2010
- Efficacy and safety of dabigatran compared with warfarin at different levels of international normalised ratio control for stroke prevention in atrial fibrillation: an analysis of the RE-LY trial. The Lancet. 376:975-983. 2010
- New antithrombotic agents—insights from clinical trials. Nature Reviews Cardiology. 7:498-509. 2010
- Warfarin after anterior myocardial infarction in current era of dual antiplatelet therapy: a randomized feasibility trial. Journal of Thrombosis and Thrombolysis. 30:127-132. 2010
- Erratum to: New pharmacotherapy for stroke prevention in atrial fibrillation. Advances in Therapy. 27:493-493. 2010
- Explaining the RE-LY Trial. Canadian Journal of Hospital Pharmacy. 63:334-336. 2010
- A National Survey of Canadian Practice Patterns of Warfarin After Anterior Wall Myocardial Infarction in the Current Era of Dual Antiplatelet Therapy. American Journal of Cardiology. 105:1844-1844. 2010
- Does dabigatran improve stroke‐prevention in atrial fibrillation? Reply to a rebuttal. Journal of Thrombosis and Haemostasis. 8:1438-1439. 2010
- Triple Antithrombotic Therapy in Patients With Atrial Fibrillation and Coronary Artery Stents. Circulation. 121:2067-2070. 2010
- Duration of red cell storage before transfusion and in-hospital mortality. American Heart Journal. 159:737-743.e1. 2010
- Point-of-care Testing for Assessment of Adequacy of Oral Antiplatelet Therapy in Patients With Cardiovascular Disease. Future Cardiology. 6:289-299. 2010
- Role of triple antithrombotic therapy in patients with atrial fibrillation and coronary artery stents. Medical Journal of Australia. 192:487-488. 2010
- New Anticoagulants. Circulation. 121:1523-1532. 2010
- Dabigatran: ready for prime time?. Polskie Archiwum Medycyny Wewnetrznej. 120:137-142. 2010
- How can we reduce disagreement among guidelines for venous thromboembolism prevention?. Journal of Thrombosis and Haemostasis. 8:675-677. 2010
- Underuse of evidence-based warfarin dosing methods for atrial fibrillation patients. Thrombosis Research. 125:e128-e131. 2010
- Response to Ticagrelor in Clopidogrel Nonresponders and Responders and Effect of Switching Therapies. Circulation. 121:1188-1199. 2010
- Antithrombotic drugs for patients with ischaemic stroke and transient ischaemic attack to prevent recurrent major vascular events. Lancet Neurology. 9:273-284. 2010
- Coagulation Factor IXa as a Target for Treatment and Prophylaxis of Venous Thromboembolism. Arteriosclerosis, Thrombosis and Vascular Biology. 30:382-387. 2010
- Rationale and design of AVERROES: Apixaban versus acetylsalicylic acid to prevent stroke in atrial fibrillation patients who have failed or are unsuitable for vitamin K antagonist treatment. American Heart Journal. 159:348-353.e1. 2010
- Comparison of the anticoagulant intensities of fondaparinux and enoxaparin in the organization to assess strategies in acute ischemic syndromes (OASIS)‐5 trial. Journal of Thrombosis and Haemostasis. 8:243-249. 2010
- Another oral thrombin inhibitor for stroke prevention in atrial fibrillation?. Thrombosis and Haemostasis. 103:481-483. 2010
- Effect of a simple two‐step warfarin dosing algorithm on anticoagulant control as measured by time in therapeutic range: a pilot study. Journal of Thrombosis and Haemostasis. 8:101-106. 2010
- Mean platelet volume as a predictor of cardiovascular risk: a systematic review and meta‐analysis. Journal of Thrombosis and Haemostasis. 8:148-156. 2010
- Relationship between baseline haemoglobin and major bleeding complications in acute coronary syndromes. European Heart Journal. 31:50-58. 2010
- The CHADS2 score for stroke risk stratification in atrial fibrillation – friend or foe?. Thrombosis and Haemostasis. 104:45-48. 2010
- Deep Vein Thrombosis Prophylaxis: Response. Chest. 136:1700-1701. 2009
- Dual antiplatelet therapy in patients requiring urgent coronary artery bypass grafting surgery: A position statement of the Canadian Cardiovascular Society. Canadian Journal of Cardiology. 25:683-689. 2009
- New pharmacotherapy for stroke prevention in atrial fibrillation: Update 2010. Advances in Therapy. 26:1058-1071. 2009
- Standardized reporting of bleeding complications for clinical investigations in acute coronary syndromes: A proposal from the Academic Bleeding Consensus (ABC) Multidisciplinary Working Group. American Heart Journal. 158:881-886.e1. 2009
- Major Bleeding, Mortality, and Efficacy of Fondaparinux in Venous Thromboembolism Prevention Trials. Circulation. 120:2006-2011. 2009
- Percutaneous closure of the left atrial appendage was noninferior to warfarin in atrial fibrillation. ACP journal club. 151. 2009
- Percutaneous closure of the left atrial appendage was noninferior to warfarin in atrial fibrillation. Annals of Internal Medicine. 151:JC5-JC5. 2009
- Anticoagulants for patients with prosthetic heart valves – Authors' reply. The Lancet. 374:1499-1500. 2009
- New Anticoagulants for Atrial Fibrillation. Seminars in Thrombosis and Hemostasis. 35:711-711. 2009
- Accelerated Infusion of Streptokinase for the Treatment of Left-Sided Prosthetic Valve Thrombosis. Circulation. 120:1108-1114. 2009
- Dabigatran versus Warfarin in Patients with Atrial Fibrillation. New England Journal of Medicine. 361:1139-1151. 2009
- Otamixaban in acute coronary syndromes. The Lancet. 374:762-764. 2009
- Prevention and treatment of bleeding complications in patients receiving vitamin K antagonists, Part 1: Prevention. American Journal of Hematology. 84:579-583. 2009
- Antithrombotic management of patients with prosthetic heart valves: current evidence and future trends. The Lancet. 374:565-576. 2009
- Rivaroxaban versus enoxaparin after total knee arthroplasty. The Lancet. 374:681-681. 2009
- Does acetyl salicylic acid (ASA) have a role in the prevention of venous thromboembolism?. British Journal of Haematology. 146:142-149. 2009
- New Anticoagulants for Atrial Fibrillation. Seminars in Thrombosis and Hemostasis. 35:515-524. 2009
- Response to Letter Regarding Article, “Incomplete Inhibition of Thromboxane Biosynthesis by Acetylsalicylic Acid: Determinants and Effect on Cardiovascular Risk”. Circulation. 119:E595-E596. 2009
- Low-Molecular-Weight Heparin as an Adjunct to Thrombolysis in ST Elevation Myocardial Infarction. JAMA Internal Medicine. 169:1163-1163. 2009
- Duration of anticoagulant therapy for venous thromboembolism. Medical Journal of Australia. 190:659-660. 2009
- Ethnicity Does Not Affect the Homocysteine-Lowering Effect of B-Vitamin Therapy in Singaporean Stroke Patients. Stroke. 40:2209-2211. 2009
- Effect of Clopidogrel Added to Aspirin in Patients with Atrial Fibrillation. New England Journal of Medicine. 360:2066-2078. 2009
- Effects of a polypill (Polycap) on risk factors in middle-aged individuals without cardiovascular disease (TIPS): a phase II, double-blind, randomised trial. The Lancet. 373:1341-1351. 2009
- Aspirin to Prevent Cardiovascular Disease: The Association of Aspirin Dose and Clopidogrel With Thrombosis and Bleeding. ACP journal club. 150:379-379. 2009
- Treatment of intermittent claudication. The BMJ. 338:b46-b46. 2009
- Anticoagulation for ST-Segment Elevation Myocardial Infarction. Circulation. 119:1186-1188. 2009
- Fondaparinux in the treatment of acute coronary syndromes: evidence from OASIS 5 and 6. Expert Review of Cardiovascular Therapy. 7:241-249. 2009
- Improving clinical outcomes by reducing bleeding in patients with non-ST-elevation acute coronary syndromes. European Heart Journal. 30:655-661. 2009
- Postoperative Low‐Molecular‐Weight Heparin Bridging Is Associated with an Increase in Wound Hematoma Following Surgery for Pacemakers and Implantable Defibrillators. PACE - Pacing and Clinical Electrophysiology. 32:378-382. 2009
- Use of antifibrinolytic therapy to reduce transfusion in patients undergoing orthopedic surgery: A systematic review of randomized trials. Thrombosis Research. 123:687-696. 2009
- American Association of Orthopedic Surgeons and American College of Chest Physicians Guidelines for Venous Thromboembolism Prevention in Hip and Knee Arthroplasty Differ. Chest. 135:513-520. 2009
- Dabigatran etexilate for prevention of venous thromboembolism. Thrombosis and Haemostasis. 101:2-4. 2009
- Effect of Long-Term Homocysteine Reduction with B Vitamins on Arterial Wall Inflammation Assessed by Fluorodeoxyglucose Positron Emission Tomography: A Randomised Double-Blind, Placebo-Controlled Trial. Cerebrovascular Diseases. 27:259-265. 2009
- New oral anticoagulants: not quite there yet. Polskie Archiwum Medycyny Wewnetrznej. 119:53-59. 2009
- Randomized trial comparing 600- with 300-mg loading dose of clopidogrel in patients with non–ST elevation acute coronary syndrome undergoing percutaneous coronary intervention: Results of the Platelet Responsiveness to Aspirin and Clopidogrel and Troponin Increment after Coronary intervention in Acute coronary Lesions (PRACTICAL) Trial. American Heart Journal. 157:60.e1-60.e9. 2009
- Platelet ADP-receptor antagonists for cardiovascular disease: past, present and future. Nature Reviews Cardiology. 5:766-780. 2008
- The Pursuit of Clinically Relevant Measures of Platelet Function After Antiplatelet Drug Therapy⁎⁎Editorials published in the Journal of the American College of Cardiology reflect the views of the authors and do not necessarily represent the views of JACC or the American College of Cardiology.. Journal of the American College of Cardiology. 52:1978-1980. 2008
- The effect of long-term homocysteine-lowering on carotid intima-media thickness and flow-mediated vasodilation in stroke patients: a randomized controlled trial and meta-analysis. BMC Cardiovascular Disorders. 8:24. 2008
- Antithrombotic Therapy With Fondaparinux in Relation to Interventional Management Strategy in Patients With ST- and Non–ST-Segment Elevation Acute Coronary Syndromes. Circulation. 118:2038-2046. 2008
- Benefit of Oral Anticoagulant Over Antiplatelet Therapy in Atrial Fibrillation Depends on the Quality of International Normalized Ratio Control Achieved by Centers and Countries as Measured by Time in Therapeutic Range. Circulation. 118:2029-2037. 2008
- Incomplete Inhibition of Thromboxane Biosynthesis by Acetylsalicylic Acid. Circulation. 118:1705-1712. 2008
- What do the results of the PRoFESS trial teach us?. Lancet Neurology. 7:860-862. 2008
- Using aspirin to prevent cognitive decline. The BMJ. 337:a958-a958. 2008
- Gastrointestinal bleeding after acute ischemic stroke. Neurology. 71:650-655. 2008
- Guidelines for anticoagulant use in acute coronary syndromes – Authors' reply. The Lancet. 372:533-534. 2008
- The incidence of venous thromboembolism: a prospective, community‐based study in Perth, Western Australia. Medical Journal of Australia. 189:144-147. 2008
- Selective factor Xa inhibition for thromboprophylaxis. The Lancet. 372:6-8. 2008
- The risk of iatrogenic bleeding in acute coronary syndromes and long-term mortality. Current Opinion in Cardiology. 23:327-334. 2008
- Homocysteine or Renal Impairment. Arteriosclerosis, Thrombosis and Vascular Biology. 28:1158-1164. 2008
- Antiplatelet Therapy for Secondary Prevention of Noncardioembolic Ischemic Stroke. Stroke. 39:1638-1646. 2008
- Clopidogrel Resistance. Journal of the American College of Cardiology. 51:1935-1937. 2008
- Guidelines for anticoagulant use in acute coronary syndromes. The Lancet. 371:1559-1561. 2008
- Clinical factors influencing the sensitivity to warfarin when restarted after surgery. Journal of Internal Medicine. 263:412-419. 2008
- Effect of fondaparinux 2.5 mg once daily on mortality: a meta-analysis of phase III randomized trials of venous thromboembolism prevention. European Heart Journal, Supplement. 10:C8-C13. 2008
- The effect of pre-operative aspirin on bleeding, transfusion, myocardial infarction, and mortality in coronary artery bypass surgery: a systematic review of randomized and observational studies. European Heart Journal. 29:1057-1071. 2008
- Will prasugrel supersede clopidogrel for acute coronary syndromes?. Medical Journal of Australia. 188:381-382. 2008
- Response to Letter Regarding Article, “Challenges of Establishing New Antithrombotic Therapies in Atrial Fibrillation”. Circulation. 117:E150-E150. 2008
- Management of peripheral arterial disease in the elderly: focus on cilostazol. Clinical interventions in aging. Volume 3:17-23. 2008
- Nonbleeding complications of unfractionated and low-molecular weight heparins.. Clinical Advances in Hematology and Oncology. 5:871-873. 2007
- Bleeding Complications in Acute Coronary Syndromes and Percutaneous Coronary Intervention: Predictors, Prognostic Significance, and Paradigms for Reducing Risk. Clinical Cardiology. 30:II24-II34. 2007
- Bleeding complications in acute coronary syndromes and percutaneous coronary intervention: predictors, prognostic significance, and paradigms for reducing risk.. Clinical Cardiology. 30:II24-II34. 2007
- Efficacy and Safety of Fondaparinux Versus Enoxaparin in Patients With Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention. Journal of the American College of Cardiology. 50:1742-1751. 2007
- Simplifying the diagnosis of pulmonary embolism. Medical Journal of Australia. 187:325-326. 2007
- Beyond Unfractionated Heparin and Warfarin. Circulation. 116:552-560. 2007
- Challenges of Establishing New Antithrombotic Therapies in Atrial Fibrillation. Circulation. 116:449-455. 2007
- Oral Anticoagulant and Antiplatelet Therapy and Peripheral Arterial Disease. New England Journal of Medicine. 357:217-227. 2007
- A Replacement for Warfarin. Circulation. 116:131-133. 2007
- Association between asymptomatic deep vein thrombosis detected by venography and symptomatic venous thromboembolism in patients undergoing elective hip or knee surgery. Journal of Thrombosis and Haemostasis. 5:1438-1443. 2007
- Role of protein Z in stroke. Current Treatment Options in Cardiovascular Medicine. 9:191-197. 2007
- Inherited thrombophilia and pregnancy associated venous thromboembolism. The BMJ. 334:1318-1321. 2007
- Latest medical treatment strategies for venous thromboembolism. Expert Opinion on Pharmacotherapy. 8:1221-1233. 2007
- Who Is (Still) Getting HIT?. Chest. 131:1620-1622. 2007
- In reply [10]. Journal of the American Medical Association (JAMA). 297:1881-1882. 2007
- Pexelizumab and the APEX AMI Trial—Reply. Journal of the American Medical Association (JAMA). 297:1877-1877. 2007
- Bleeding and blood transfusion issues in patients with non-ST-segment elevation acute coronary syndromes. European Heart Journal. 28:1193-1204. 2007
- VITATOPS, the VITAmins TO Prevent Stroke Trial: Rationale and Design of a Randomised Trial of B-Vitamin Therapy in Patients with Recent Transient Ischaemic Attack or Stroke (NCT00097669) (ISRCTN74743444). International Journal of Stroke. 2:144-150. 2007
- Platelet Function Testing: Quality Assurance. Seminars in Thrombosis and Hemostasis. 33:273-282. 2007
- Anticoagulation for venous thromboembolism. The BMJ. 334:645-645. 2007
- Treatment of Restenosis with a Paclitaxel-Coated Balloon Catheter. New England Journal of Medicine. 356:1071-1073. 2007
- Antithrombotic treatment for peripheral arterial disease. Heart. 93:303-308. 2007
- Pexelizumab Does Not “Complement” Percutaneous Coronary Intervention in Patients With ST-Elevation Myocardial Infarction. Journal of the American Medical Association (JAMA). 297:91-91. 2007
- Aspirin resistance. Thrombosis Research. 120:337-346. 2007
- Guidelines for the management of acute coronary syndromes 2006. Medical Journal of Australia. 186:101-102. 2007
- Clinical update on the therapeutic use of clopidogrel: treatment of acute ST-segment elevation myocardial infarction (STEMI). Vascular Health and Risk Management. 2:379-387. 2006
- Bleeding and management of bleeding. European Heart Journal, Supplement. 8:G38-G45. 2006
- The tissue factor pathway in ischemic stroke. Blood Coagulation and Fibrinolysis. 17:527-532. 2006
- Association between phosphodiesterase 4D gene and ischaemic stroke. Journal of Neurology, Neurosurgery and Psychiatry. 77:1067-1069. 2006
- Homocysteine-Should We Screen and Treat in Preventive Cardiology Programs?. Journal of Cardiopulmonary Rehabilitation and Prevention. 26:281-287. 2006
- Adverse Impact of Bleeding on Prognosis in Patients With Acute Coronary Syndromes. Circulation. 114:774-782. 2006
- Adverse impact of bleeding on prognosis in patients with acute coronary syndromes. Circulation. 114:774-782. 2006
- ESPRIT trial. The Lancet. 368:447-447. 2006
- The Outpatient Bleeding Risk Index predicted major bleeding in patients taking warfarin. BMJ Evidence-Based Medicine. 11:120-120. 2006
- Medical Management of Peripheral Arterial Disease—Reply. Journal of the American Medical Association (JAMA). 296:41-41. 2006
- Treatment of Antiphospholipid Antibody Syndrome—Reply. Journal of the American Medical Association (JAMA). 296:42-42. 2006
- More on: enhanced antiplatelet effect of clopidogrel in patients whose platelets are least inhibited by aspirin: a randomized crossover trial. Journal of Thrombosis and Haemostasis. 4:1639-1640. 2006
- Enoxaparin versus Unfractionated Heparin in ST-Elevation Myocardial Infarction. New England Journal of Medicine. 354:2830-2832. 2006
- Management of antiphospholipid antibody syndrome.. Journal of Family Practice. 55:479. 2006
- Meta-Analysis: Low-Molecular-Weight Heparin and Bleeding in Patients with Severe Renal Insufficiency. ACP journal club. 144:673-673. 2006
- Risk of Recurrent Venous Thromboembolism in Patients With Common Thrombophilia. JAMA Internal Medicine. 166:729-729. 2006
- Aspirin resistance: does it exist and is it an important clinical problem?. Clinical Advances in Hematology and Oncology. 4:268-270. 2006
- Management of Antiphospholipid Antibody Syndrome. Journal of the American Medical Association (JAMA). 295:1050-1050. 2006
- Aspirin resistance. The Lancet. 367:606-617. 2006
- Homocysteine-lowering trials for prevention of cardiovascular events: A review of the design and power of the large randomized trials. American Heart Journal. 151:282-287. 2006
- Medical Treatment of Peripheral Arterial Disease. Journal of the American Medical Association (JAMA). 295:547-547. 2006
- Methylenetetrahydrofolate Reductase Polymorphisms and Homocysteine-Lowering Effect of Vitamin Therapy in Singaporean Stroke Patients. Stroke. 37:456-460. 2006
- Monitoring unfractionated heparin with the aPTT: Time for a fresh look. Thrombosis and Haemostasis. 96:547-552. 2006
- Unfractionated and Low-Molecular-Weight Heparin as Adjuncts to Thrombolysis in Aspirin-Treated Patients With ST-Elevation Acute Myocardial Infarction. Circulation. 112:3855-3867. 2005
- Enhanced antiplatelet effect of clopidogrel in patients whose platelets are least inhibited by aspirin: a randomized crossover trial. Journal of Thrombosis and Haemostasis. 3:2649-2655. 2005
- Direct thrombin inhibitors in acute coronary syndromes: effect in patients undergoing early percutaneous coronary intervention. European Heart Journal. 26:2396-2403. 2005
- Warfarin was not more effective than aspirin and increased adverse events in symptomatic intracranial arterial stenosis. BMJ Evidence-Based Medicine. 10:136-136. 2005
- Low-dose aspirin lowered stroke risk but not risk for MI or cardiovascular death in women. ACP journal club. 143:33-33. 2005
- Protein Z Levels, Protein Z G79A Polymorphism, and Prothrombotic Conditions. Stroke. 36:1821-1822. 2005
- Warfarin was not more effective than aspirin and increased adverse events in symptomatic intracranial arterial stenosis. ACP journal club. 143:32-32. 2005
- von Willebrand Disease Associated with Superficial Temporal Artery Pseudoaneurysm. European Journal of Vascular and Endovascular Surgery. 30:285-287. 2005
- Venous thromboembolism: diagnosis and management of pulmonary embolism - Reply. Medical Journal of Australia. 183:221-221. 2005
- Venous thromboembolism: diagnosis and management of pulmonary embolism.. Medical Journal of Australia. 183:220-221. 2005
- Venous thromboembolism: diagnosis and management of pulmonary embolism. Medical Journal of Australia. 183:220-221. 2005
- Aspirin resistance and its implications in clinical practice.. Medscape women's health [electronic resource]. 7:76. 2005
- Aspirin resistance: position paper of the Working Group on Aspirin Resistance. Journal of Thrombosis and Haemostasis. 3:1309-1311. 2005
- Bone marrow biopsy morbidity and mortality: 2002 data.. International Journal of Laboratory Hematology. 27:209-210. 2005
- Protein Z Gene Polymorphisms, Protein Z Concentrations, and Ischemic Stroke. Stroke. 36:1123-1127. 2005
- Venous thromboembolism: diagnosis and management of pulmonary embolism. Medical Journal of Australia. 182:569-574. 2005
- Letters Regarding Article by Mehilli et al, "Randomized Clinical Trial of Abciximab in Diabetic Patients Undergoing Elective Percutaneous Coronary Interventions After Treatment With a High Loading Dose of Clopidogrel" * Response. Circulation. 111:e370-e371. 2005
- Bone marrow biopsy in thrombocytopenic or anticoagulated patients. British Journal of Haematology. 129:562-563. 2005
- High prevalence of abnormal preoperative coagulation tests in patients with adolescent idiopathic scoliosis. Journal of Thrombosis and Haemostasis. 3:1094-1095. 2005
- Venous thromboembolism: diagnosis and management of deep venous thrombosis. Medical Journal of Australia. 182:476-481. 2005
- Adding aspirin to clopidogrel after TIA and ischemic stroke. Neurology. 64:1117-1121. 2005
- Prophylactic use of LMWH plus intermittent pneumatic compression prevented DVT in hip or knee arthroplasty. BMJ Evidence-Based Medicine. 10:48-48. 2005
- Review: thrombolytic treatment does not reduce the risk of recurrent pulmonary embolism and death more than heparin. BMJ Evidence-Based Medicine. 10:41-41. 2005
- Cardiovascular safety of rofecoxib (Vioxx): lessons learned and unanswered questions. Medical Journal of Australia. 182:199-199. 2005
- Homocysteine and stroke. The Lancet. 365:194-196. 2005
- Congestive heart failure complicating non-ST segment elevation acute coronary syndrome: incidence, predictors, and clinical outcomes. Canadian Journal of Physiology and Pharmacology. 83:98-103. 2005
- Homocysteine-Lowering Treatment With Folic Acid, Cobalamin, and Pyridoxine Does Not Reduce Blood Markers of Inflammation, Endothelial Dysfunction, or Hypercoagulability in Patients With Previous Transient Ischemic Attack or Stroke. Stroke. 36:144-146. 2005
- Sustained Homocysteine-Lowering Effect over Time of Folic Acid-Based Multivitamin Therapy in Stroke Patients despite Increasing Folate Status in the Population. Cerebrovascular Diseases. 19:110-116. 2005
- Cardiovascular safety of rofecoxib (Vioxx): lessons learned and unanswered questions. Medical Journal of Australia. 181:524-525. 2004
- Measurement of soluble P‐selectin and soluble CD40 ligand in serum and plasma. Journal of Thrombosis and Haemostasis. 2:2067-2069. 2004
- Low-Molecular-Weight Heparin for Pulmonary Embolism. ACP journal club. 141:407-407. 2004
- Low-Molecular-Weight Heparin for Pulmonary Embolism. ACP journal club. 141:407-407. 2004
- Clinical usefulness of plasma homocysteine in vascular disease. Medical Journal of Australia. 181:314-318. 2004
- Review: clinical gestalt strategies and clinical prediction rules have similar discriminate pretest probabilities of pulmonary embolism. BMJ Evidence-Based Medicine. 9:155-155. 2004
- Thrombolysis Compared With Heparin for the Initial Treatment of Pulmonary Embolism. Circulation. 110:744-749. 2004
- Folic Acid–Based Multivitamin Therapy to Prevent Stroke. Stroke. 35:1995-1998. 2004
- Is There Really a Power Shortage in Clinical Trials Testing the “Homocysteine Hypothesis?”. Arteriosclerosis, Thrombosis and Vascular Biology. 24:e147. 2004
- Peripheral arterial disease: prognostic significance and prevention of atherothrombotic complications. Medical Journal of Australia. 181:150-154. 2004
- Evaluation of the phospholipid-rich dilute Russell's viper venom assay to monitor oral anticoagulation in patients with lupus anticoagulant. Blood Coagulation and Fibrinolysis. 15:353-357. 2004
- Evaluation of the phospholipid-rich dilute Russell's viper venom assay to monitor oral anticoagulation in patients with lupus anticoagulant.. Blood Coagulation and Fibrinolysis. 15:353-357. 2004
- The beginning of the end of warfarin?. Medical Journal of Australia. 180:549-551. 2004
- Thromboprophylaxis practice patterns in two Western Australian teaching hospitals.. Haematologica. 89:586-593. 2004
- High- and moderate-intensity warfarin regimens did not differ for preventing thrombosis in the antiphospholipid antibody syndrome. ACP journal club. 140:38-38. 2004
- Is there a role for laboratory testing to identify patients at risk of aspirin treatment failure?. Blood Coagulation and Fibrinolysis. 15:129-130. 2004
- Is there a role for laboratory testing to identify patients at risk of aspirin treatment failure?. Blood Coagulation and Fibrinolysis. 15:129-130. 2004
- Prevention of coronary heart disease with aspirin and clopidogrel: efficacy, safety, costs and cost-effectiveness. Expert Opinion on Pharmacotherapy. 5:493-503. 2004
- Renal Function, Peak Anti‐Xa Levels and Enoxaparin Dosing. Journal of Pharmacy Practice and Research. 34:14-17. 2004
- Aspirin resistance: Table 1. The BMJ. 328:477-477. 2004
- Low-Molecular-Weight Heparin Compared with Intravenous Unfractionated Heparin for Treatment of Pulmonary Embolism. ACP journal club. 140:175-175. 2004
- Ximelagatran or Warfarin for Stroke Prevention in Patients With Atrial Fibrillation?. Stroke. 35:389-391. 2004
- Ximelagatran or warfarin in atrial fibrillation?. The Lancet. 363:734-734. 2004
- Adjunctive Use of Direct Thrombin Inhibitors in Patients Receiving Fibrinolytic Therapy for Acute Myocardial Infarction. American Journal of Cardiovascular Drugs. 4:107-115. 2004
- Failure of Aspirin to Prevent Atherothrombosis. American Journal of Cardiovascular Drugs. 4:57-67. 2004
- Prevention of coronary heart disease with aspirin and clopidogrel: efficacy, safety, costs and cost-effectiveness. Expert Opinion on Pharmacotherapy. 5:493-503. 2004
- Red cell N5-methyltetrahydrofolate concentrations and C677T methylenetetrahydrofolate reductase genotype in patients with stroke. Journal of Clinical Pathology - Clinical Molecular Pathology. 57:54-57. 2004
- Does This Patient Have Pulmonary Embolism?. Journal of the American Medical Association (JAMA). 290:2849-2849. 2003
- Normal plasma mixing studies in the laboratory diagnosis of lupus anticoagulant. Journal of Thrombosis and Haemostasis. 1:2689-2691. 2003
- Recombinant activated factor VII for the treatment of life-threatening haemorrhage. Blood Coagulation and Fibrinolysis. 14:713-717. 2003
- Cyclooxygenase-2 Inhibitors. Stroke. 34:2736-2740. 2003
- SUBOPTIMAL PREVENTIVE PRACTICES IN PATIENTS WITH CAROTID AND PERIPHERAL VASCULAR OCCLUSIVE DISEASE IN A TERTIARY REFERRAL SETTING. ANZ Journal of Surgery. 73:932-937. 2003
- Protein Z in Ischemic Stroke and its Etiologic Subtypes. Stroke. 34:2415-2419. 2003
- Thromboprophylaxis practice patterns in hip fracture surgery patients: experience in Perth, Western Australia. ANZ Journal of Surgery. 73:826-829. 2003
- Venous thromboembolism in travellers. Blood Coagulation and Fibrinolysis. 14:671-675. 2003
- Venous thromboembolism in travellers: can we identify those at risk?. Blood Coagulation and Fibrinolysis. 14:671-675. 2003
- Endothelial and Platelet Activation in Acute Ischemic Stroke and Its Etiological Subtypes. Stroke. 34:2132-2137. 2003
- Editorial Comment—Routine Thrombophilia Testing in Stroke Patients Is Unjustified. Stroke. 34:1826-1827. 2003
- Long‐term management of venous thromboembolism: is there a role for low‐intensity warfarin therapy?. Medical Journal of Australia. 179:68-69. 2003
- Antiplatelet drugs. Medical Journal of Australia. 178:568-574. 2003
- Collagen platelet receptor polymorphisms integrin α2β1 C807T and GPVI Q317L and risk of ischemic stroke. Journal of Thrombosis and Haemostasis. 1:963-970. 2003
- Review: MTHFR TT genotype increases risk for coronary heart disease. ACP journal club. 138:79-79. 2003
- In reply: Low‐molecular‐weight heparins and heparinoids. Medical Journal of Australia. 178:414-415. 2003
- Low‐molecular‐weight heparins and heparinoids. Medical Journal of Australia. 178:413-414. 2003
- Aspirin resistance:a new independent predictor of vascular events?**Editorials published in the Journal of the American College of Cardiologyreflect the views of the authors and do no necessarily represent the views of JACCor the American College of Cardiology.. Journal of the American College of Cardiology. 41:966-968. 2003
- C-reactive protein in ischemic stroke and its etiologic subtypes. Journal of Stroke and Cerebrovascular Diseases. 12:74-81. 2003
- Homocysteine-lowering therapy improved outcomes after percutaneous coronary intervention. ACP journal club. 138:33-33. 2003
- The evolving role of direct thrombin inhibitors in acute coronary syndromes.. Journal of the American College of Cardiology. 41:70S-78S. 2003
- The evolving role of direct thrombin inhibitors in acute coronary syndromes. Journal of the American College of Cardiology. 41:S70-S78. 2003
- Antiplatelet Agents in Acute Coronary Syndromes. Seminars in Thrombosis and Hemostasis. 03:403-414. 2003
- Untitled - Response. Circulation. 106:E200-E201. 2002
- Reasons for Resistance to Aspirin in Cardiovascular Disease. Circulation. 106:1-2. 2002
- Reasons for resistance to aspirin in cardiovascular disease.. Circulation. 106:e181-e182. 2002
- Clopidogrel does not suppress blood markers of coagulation activation in aspirin-treated patients with non-ST-elevation acute coronary syndromes. European Heart Journal. 23:1771-1779. 2002
- Recurrent palmar–plantar erythrodysaesthesia following high‐dose cytarabine treatment for acute lymphoblastic leukemia. European Journal of Haematology. 69:315-317. 2002
- Aspirin for the primary prevention of cardiovascular events. Medical Journal of Australia. 177:343-344. 2002
- Low molecular weight heparins and heparinoids. Medical Journal of Australia. 177:379-383. 2002
- Direct thrombin inhibitors in acute coronary syndromes. The Lancet. 360:491-492. 2002
- Direct thrombin inhibitors in acute coronary syndromes. The Lancet. 360:492-492. 2002
- Short-Duration Prophylaxis Against Venous Thromboembolism After Total Hip or Knee Replacement. JAMA Internal Medicine. 162:1465-1465. 2002
- The tip of the iceberg?. The Lancet. 359:2194-2194. 2002
- Cyclooxygenase Inhibitors and the Antiplatelet Effects of Aspirin. New England Journal of Medicine. 346:1589-1590. 2002
- Cyclooxygenase inhibitors and the antiplatelet effects of aspirin. New England Journal of Medicine. 346:1589-1589. 2002
- Aspirin-Resistant Thromboxane Biosynthesis and the Risk of Myocardial Infarction, Stroke, or Cardiovascular Death in Patients at High Risk for Cardiovascular Events. Circulation. 105:1650-1655. 2002
- Efficacy of hirudin in reducing cardiovascular events in patients with acute coronary syndrome undergoing early percutaneous coronary intervention. European Heart Journal. 23:117-123. 2002
- Direct thrombin inhibitors in acute coronary syndromes: principal results of a meta-analysis based on individual patients' data. The Lancet. 359:294-302. 2002
- Management of Patients with Acute Coronary Syndromes. Drugs. 62:1839-1852. 2002
- The VITATOPS (Vitamins to Prevent Stroke) Trial: Rationale and Design of an International, Large, Simple, Randomised Trial of Homocysteine-Lowering Multivitamin Therapy in Patients with Recent Transient Ischaemic Attack or Stroke. Cerebrovascular Diseases. 13:120-126. 2002
- Effects of Clopidogrel in Addition to Aspirin in Patients with Acute Coronary Syndromes without ST-Segment Elevation. New England Journal of Medicine. 345:494-502. 2001
- Inherited Thrombophilia in Ischemic Stroke and Its Pathogenic Subtypes. Stroke. 32:1793-1799. 2001
- Extended-duration prophylaxis against venous thromboembolism after total hip or knee replacement: a meta-analysis of the randomised trials. The Lancet. 358:9-15. 2001
- Platelet glycoprotein Ibα Kozak polymorphism is associated with an increased risk of ischemic stroke. Blood. 98:36-40. 2001
- Routine home treatment of deep vein thrombosis. The BMJ. 322:1192-1193. 2001
- Routine home treatment of deep vein thrombosis - Is now a reality. The BMJ. 322:1192-1193. 2001
- Associations of homocysteine, C-reactive protein and cardiovascular disease in patients with renal disease. Current Opinion in Nephrology and Hypertension. 10:377-383. 2001
- Safety of Bolus vs Infusion Thrombolytic Therapy. Journal of the American Medical Association (JAMA). 285:2075-2075. 2001
- Prognostic Significance of Thrombocytopenia During Hirudin and Heparin Therapy in Acute Coronary Syndrome Without ST Elevation. Circulation. 103:643-650. 2001
- Homocysteine and stroke. Current Opinion in Neurology. 14:95-102. 2001
- Safety Outcomes in Meta-analyses of Phase 2 vs Phase 3 Randomized Trials. Journal of the American Medical Association (JAMA). 285:444-444. 2001
- Homocysteine Levels in Patients with Stroke. CNS Drugs. 15:437-443. 2001
- Impact of right ventricular involvement on mortality and morbidity in patients with inferior myocardial infarction11Drs. Mehta and Eikelboom were recipients of Heart and Stroke Foundation of Canada Research Fellowship Awards. Professor Yusuf is the recipient of a Medical Research Council of Canada Senior Scientist Award and holds a Heart and Stroke Foundation of Ontario Research Chair.. Journal of the American College of Cardiology. 37:37-43. 2001
- The Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) trial programme. Rationale, design and baseline characteristics including a meta-analysis of the effects of thienopyridines in vascular disease. European Heart Journal. 21:2033-2041. 2000
- Treatment of Proximal Deep Vein Thrombosis With a Novel Synthetic Compound (SR90107A/ORG31540) With Pure Anti–Factor Xa Activity. Circulation. 102:2726-2731. 2000
- Venous Thromboembolism and Cancer. New England Journal of Medicine. 343:1337-1338. 2000
- Intracranial haemorrhage with bolus thrombolytic agents. The Lancet. 356:1850-1850. 2000
- Intracranial haemorrhage with bolus thrombolytic agents. The Lancet. 356:1848-1848. 2000
- Management of unstable angina and myocardial infarction. The Lancet. 356:1193-1194. 2000
- Erratum: Unfractionated heparin and low-molecular-weight heparin in acute coronary syndrome without ST elevation: A meta-analysis (Lancet (2000) 3 June (1936)). The Lancet. 356:600. 2000
- Unfractionated heparin and low-molecular-weight heparin in acute coronary syndrome without ST elevation: a meta-analysis (vol 355, pg 1936, 2000). The Lancet. 356:600-600. 2000
- Risk of intracranial haemorrhage with bolus versus infusion thrombolytic therapy: a meta-analysis. The Lancet. 356:449-454. 2000
- Unfractionated heparin and low-molecular-weight heparin in acute coronary syndrome without ST elevation: a meta-analysis. The Lancet. 355:1936-1942. 2000
- Association Between High Homocyst(e)ine and Ischemic Stroke due to Large- and Small-Artery Disease but Not Other Etiologic Subtypes of Ischemic Stroke. Stroke. 31:1069-1075. 2000
- Homocyst(e)ine and Cardiovascular Disease. ACP journal club. 132:676-676. 2000
- Homocyst(e)ine and Cardiovascular Disease. ACP journal club. 132:676-676. 2000
- Review: high levels of homocysteine are associated with an increased risk for cardiovascular disease. BMJ Evidence-Based Medicine. 5:63-63. 2000
- Management of unstable coronary-artery disease. The Lancet. 355:572-572. 2000
- Detection of protein s deficiency: a new functional assay compared to an antigenic technique. Pathology. 32:94-97. 2000
- Homocysteine and vascular disease.. Indian Heart Journal. 52:S18-S26. 2000
- Prothrombin 20210A and familial thrombophilia. Blood Coagulation and Fibrinolysis. 10:523-527. 1999
- Low rates of preventive practices in patients with peripheral vascular disease.. Canadian Journal of Cardiology. 15:1259-1263. 1999
- Homocyst(e)ine and Cardiovascular Disease: A Critical Review of the Epidemiologic Evidence. ACP journal club. 131:363-363. 1999
- Homocysteine and cardiovascular risk: is it time to treat?. Evidence-based Cardiovascular Medicine. 3:59-60. 1999
- Homocysteine and vascular disease. The Lancet. 354:407-413. 1999
- Broadsheet number 53: activated protein c resistance: diagnosis and clinical management. Pathology. 31:365-371. 1999
- Familial thrombophilia and the prothrombin 20210A mutation. Blood Coagulation and Fibrinolysis. 10:1-6. 1999
- Preventing Thromboembolic Complications in Older Orthopaedic Surgery Patients. Drugs and Aging. 15:297-306. 1999
- Methylene tetrahydrofolate reductase mutation and stroke in a monozygotic twin. Internal Medicine Journal. 28:849-850. 1998
- Low-molecular-weight Heparin for the treatment of venous thrombosis in patients with adenocarcinoma. American Journal of Hematology. 59:260-261. 1998
- Venous thrombosis and hyperhomocysteinaemia. Medical Journal of Australia. 169:313-315. 1998
- No Association between the 20210 G/A Prothrombin Gene Mutation and Premature Coronary Artery Disease. Thrombosis and Haemostasis. 80:878-880. 1998
- The effect of platelet derived microvesicles on activated protein C (APC) resistance. Australian Journal of Medical Science. 18:135. 1997
- Exacerbation of coagulopathy with concurrent bone marrow necrosis, hepatic and renal dysfunction secondary to all-trans retinoic acid therapy for acute promyelocytic leukemia. Hematological Oncology. 15:13-17. 1997
- Hepatitis C genotypes in Australian haemophilia patients. Internal Medicine Journal. 26:789-792. 1996
- Does activated protein C resistance increase the risk of systemic embolism in non rheumatic atrial fibrillation?. Internal Medicine Journal. 26:243-244. 1996
- Time for a new acute myeloid leukaemia classification?. British Journal of Haematology. 92:247-248. 1996
- Iron incorporation into ferritin and hemoglobin during differentiation of murine erythroleukemia cells. Blood. 58:255-262. 1981